Arno Therapeutics 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 25, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	Arno Therapeutics, Inc
Entity Central Index Key	1195116
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$36,259,189
Trading Symbol	ARNI
Entity Common Stock, Shares Outstanding		20,408,616

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$7,948,436	$26,774,203
Prepaid expenses and other current assets	258,046	86,266
Total current assets	8,206,482	26,860,469
Property and equipment, net	30,730	11,720
Security deposit	10,455	10,455
Total assets	8,247,667	26,882,644
Current liabilities
Accounts payable	742,448	2,941,998
Accrued expenses and other current liabilities	1,410,293	925,255
Capital lease obligation- short term	3,322	0
Due to related party	0	26,039
Deferred rent	1,048	7,797
Total current liabilities	2,157,111	3,901,089
Capital lease obligation- long term	7,923	0
Derivative liabilities	6,671,524	35,864,881
Total liabilities	8,836,558	39,765,970
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 35,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value, 500,000,000 shares authorized, 20,408,616 and 20,370,331 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively	5,469	5,465
Additional paid-in capital	81,192,630	76,668,966
Accumulated deficit	-81,786,990	-89,557,757
Total stockholders' deficit	-588,891	-12,883,326
Total liabilities and stockholders' deficit	$8,247,667	$26,882,644

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	35,000,000	35,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,408,616	20,370,331
Common stock, shares outstanding	20,408,616	20,370,331

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$14,840,302	$13,476,369
General and administrative	6,653,024	3,464,180
Total operating expenses	21,493,326	16,940,549
Loss from operations	-21,493,326	-16,940,549
Other income (expense):
Interest income	41,954	17,737
Interest expense	-143	-18,569,157
Other income (expense)	29,222,282	-4,165,006
Total other income (expense)	29,264,093	-22,716,426
Net income/(loss)	$7,770,767	($39,656,975)
Net income/(loss) per share - basic	$0.38	($5.28)
Weighted-average shares outstanding- basic	20,381,554	7,516,223
Net income/(loss) per share - diluted	$0.31	($5.28)
Weighted-average shares outstanding- diluted	24,809,995	7,516,223

STATEMENTS_OF_STOCKHOLDERS_DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)	Total	PREFERRED STOCK	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT
Beginning Balance at Dec. 31, 2012	($12,265,832)	$0	$3,611	$37,631,339	($49,900,782)
Beginning Balance (in shares) at Dec. 31, 2012		0	4,545,618
Net income/(loss)	-39,656,975	0	0	0	-39,656,975
Stock based compensation for services	1,456,776	0	0	1,456,776	0
Issuance of common shares in lieu of liquidated damages	913,510	0	305	913,205	0
Issuance of common shares in lieu of liquidated damages (in shares)		0	380,606
Issuance of common shares upon debenture conversions and in satisfaction of accrued interest	22,277,098	0	708	22,276,390	0
Issuance of common shares upon debenture conversions and in satisfaction of accrued interest (in shares)		0	7,030,753
Common stock sold in private placement, net of issuance costs of $766,803	9,158,253	0	841	9,157,412	0
Common stock sold in private placement, net of issuance costs of $766,803 (in shares)		0	8,413,354
Issuance of units	5,233,844	0	0	5,233,844	0
Ending Balance at Dec. 31, 2013	-12,883,326	0	5,465	76,668,966	-89,557,757
Ending Balance (in shares) at Dec. 31, 2013		0	20,370,331
Net income/(loss)	7,770,767	0	0	0	7,770,767
Stock based compensation for services	4,523,668	0	0	4,523,668	0
Issuance of common stock	0	0	4	-4
Issuance of common stock (in shares)		0	38,285
Ending Balance at Dec. 31, 2014	($588,891)	$0	$5,469	$81,192,630	($81,786,990)
Ending Balance (in shares) at Dec. 31, 2014		0	20,408,616

STATEMENTS_OF_STOCKHOLDERS_DEF1

STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013
Stock issuance costs	$766,803

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income/(loss)	$7,770,767	($39,656,975)
Adjustment to reconcile net income/(loss) to net cash and cash equivalents used in operating activities:
Depreciation and amortization	12,586	13,117
Stock-based compensation	4,523,668	1,456,776
Change in fair value of derivative liability	-29,193,357	4,166,454
Noncash interest expense	0	18,996,553
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	-171,780	117,250
Accounts payable	-2,199,550	1,388,844
Accrued expenses	485,038	-717,452
Deferred rent	-6,749	-4,914
Due to related party	-26,039	-2,229
Net cash used in operating activities	-18,805,416	-14,242,576
Cash flows from investing activities:
Purchase of property and equipment	-20,096	0
Payment of capital lease obligation	-255	0
Net cash used in investing activities	-20,351	0
Cash flows from financing activities:
Proceeds from issuance of units in private placement, net	0	19,425,340
Proceeds from issuance of warrants	0	10,648,002
Net cash provided by financing activities	0	30,073,342
Net increase/(decrease) in cash and cash equivalents	-18,825,767	15,830,766
Cash and cash equivalents at beginning of period	26,774,203	10,943,437
Cash and cash equivalents at end of period	7,948,436	26,774,203
Supplemental schedule of cash flows information:
Cash paid for interest	143	157,284
Supplemental schedule of non-cash investing and financing activities:
Acquisition of equipment pursuant to capital leases	11,500	0
Conversion of debentures into common stock	0	14,293
Issuance of common shares in lieu of liquidated damages	0	913,510
Issuance of common shares in lieu of accrued and additional interest	$0	$2,016,804

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2014
Business Combination, Description [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS
	Arno Therapeutics, Inc. (“Arno” or the “Company”) is developing innovative drug candidates intended to treat patients with cancer and other life threatening diseases. The Company was incorporated in Delaware in March 2000, at which time its name was Laurier International, Inc. (“Laurier”). Pursuant to an Agreement and Plan of Merger dated March 6, 2008 (as amended, the “Merger Agreement”), by and among the Company, Arno Therapeutics, Inc., a Delaware corporation formed on August 1, 2005 (“Old Arno”), and Laurier Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Laurier Acquisition”), on June 3, 2008, Laurier Acquisition merged with and into Old Arno, with Old Arno remaining as the surviving corporation and a wholly-owned subsidiary of Laurier. Immediately following this merger, Old Arno merged with and into Laurier and Laurier’s name was changed to Arno Therapeutics, Inc. These two merger transactions are hereinafter collectively referred to as the “Merger.” Immediately following the Merger, the former stockholders of Old Arno collectively held 95% of the outstanding common stock of Laurier, assuming the issuance of all shares issuable upon the exercise of outstanding options and warrants, and all of the officers and directors of Old Arno in office immediately prior to the Merger were appointed as the officers and directors of Laurier immediately following the Merger. Further, Laurier was a non-operating shell company prior to the Merger. The merger of a private operating company into a non-operating public shell corporation with nominal net assets is considered to be a capital transaction in substance, rather than a business combination, for accounting purposes. Accordingly, the Company treated this transaction as a capital transaction without recording goodwill or adjusting any of its other assets or liabilities. All costs incurred in connection with the Merger have been expensed. Upon completion of the Merger, the Company adopted Old Arno’s business plan.

LIQUIDITY_AND_CAPITAL_RESOURCE

LIQUIDITY AND CAPITAL RESOURCES	12 Months Ended
	Dec. 31, 2014
Working Capital Information [Abstract]
LIQUIDITY AND CAPITAL RESOURCES	2. LIQUIDITY AND CAPITAL RESOURCES
	Cash resources as of December 31, 2014 were approximately $7.9 million, compared to approximately $26.8 million as of December 31, 2013. Based on its resources at December 31, 2014, and the current plan of expenditure for continuing the development of the Company’s current product candidates, the Company believes that it has sufficient capital to fund its operations into the third quarter of 2015. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability from operations, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or from a transaction in which it would license rights to its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs.
	The long-term success of the Company depends on its ability to develop new products to the point of regulatory approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these developmental efforts. Management plans to raise additional capital either by selling shares of its stock or other securities, issuing additional indebtedness or by licensing the rights to one or more of its product candidates to finance the continued operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s product candidates, acquire rights to additional product candidates and for other working capital purposes. While the Company will extend its best efforts to raise additional capital to fund all operations through the third quarter of 2015 and beyond, management can provide no assurances that the Company will be successful in raising sufficient funds.
	In addition, to the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable to the Company. Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.
	These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments that might result from the inability of the Company to continue as a going concern.

THE_MERGER_AND_BASIS_OF_PRESEN

THE MERGER AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2014
Mergers Acquisitions And Dispositions Disclosures [Abstract]
THE MERGER AND BASIS OF PRESENTATION	3. THE MERGER AND BASIS OF PRESENTATION
	The accompanying audited financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the instructions to Form 10-K promulgated by the Securities and Exchange Commission (“SEC”).
	(a) Description of the Merger and Private Placement Offering
	The Company completed the Merger on June 3, 2008.   In accordance with the terms of the Merger, each share of common stock of Old Arno that was outstanding immediately prior to the Merger was exchanged for 1.99377 shares of the Company’s common stock.  In addition, all securities convertible into or exercisable for shares of Old Arno common stock outstanding immediately prior to the Merger were cancelled, and the holders thereof received similar securities convertible into or exercisable for the purchase of an aggregate of 1,611,760 shares of the Company’s common stock. In consideration for their shares of the Company’s pre-merger common stock, the Company’s shareholders received an aggregate of 19,291,824 shares of Laurier common stock.  Immediately prior to the effective time of the Merger, 1,100,200 shares of Laurier’s common stock were issued and outstanding. Upon completion of the Merger, the Old Arno shareholders owned approximately 95% of the Company’s issued and outstanding common stock, assuming the exercise of all of the issued and outstanding common stock options and warrants.
	Following the Merger, the business conducted by the Company is the business conducted by Old Arno prior to the Merger. In addition, the directors and officers of Laurier were replaced by the directors and officers of Old Arno.
	As a condition and immediately prior to the closing of the Merger, on June 2, 2008, Old Arno completed a private placement of its equity securities whereby it received gross proceeds of approximately $17,732,000 through the sale of approximately 3,691,900 shares of Old Arno Common Stock to selected accredited investors, which shares were exchanged for approximately 7,360,700 shares of Company Common Stock after giving effect to the Merger. Contemporaneously with the June 2008 private placement, the Old Arno’s outstanding 6% Notes converted into 984,246 shares of Old Arno’s common stock and the holders of the Notes received warrants to purchase an aggregate of 98,409 shares of Old Arno common stock at an exercise price equal to $4.83 per share. The shares issued upon conversion were exchanged for an aggregate of approximately 1,962,338 shares of the Company’s Common Stock and the warrants were exchanged for five-year warrants to purchase an aggregate of approximately 196,189 shares of the Company’s Common Stock at an exercise price equal to $2.42 per share.
	All references to share and per share amounts in these financial statements have been restated to retroactively reflect the number of common shares of Arno common stock issued pursuant to the Merger.
	(b) Accounting Treatment of the Merger; Financial Statement Presentation
	The Merger was accounted for as a reverse acquisition pursuant to Accounting Standards Codification (“ASC”) 805-40-25, which provides that the “merger of a private operating company into a non-operating public shell corporation with nominal net assets typically results in the owners and management of the private company having actual or effective operating control of the combined company after the transaction, with the shareholders of the former public shell continuing only as passive investors. These transactions are considered by the Securities and Exchange Commission to be capital transactions in substance, rather than business combinations. That is, the transaction is equivalent to the issuance of stock by the private company for the net monetary assets of the shell corporation, accompanied by a recapitalization.” Accordingly, the Merger has been accounted for as a recapitalization, and, for accounting purposes, Old Arno is considered the acquirer in a reverse acquisition.
	Laurier’s  historical accumulated deficit for periods prior to June 3, 2008, in the amount of $120,538, was eliminated against additional-paid-in-capital, and the accompanying financial statements present the previously issued shares of Laurier common stock as having been issued pursuant to the Merger on June 3, 2008. The shares of common stock of the Company issued to the Old Arno stockholders in the Merger are presented as having been outstanding since August 2005 (the month when Old Arno first sold its equity securities).
	Because the Merger was accounted for as a reverse acquisition under GAAP, the financial statements for periods prior to June 3, 2008 reflect only the operations of Old Arno.
	(c) Reverse Stock Split
	Effective as of the close of business on October 29, 2013, the Company amended its Amended and Restated Certificate of Incorporation to effect a combination (“Reverse Stock Split”) of the Common Stock at a ratio of one-for-eight.  All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) Use of Estimates
	The preparation of financial statements in conformity with GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees, directors and consultants, valuation of derivatives and estimates of the probability and potential magnitude of contingent liabilities. Actual results could differ from those estimates.
	(b) Cash and Cash Equivalents
	The Company considers all highly liquid investments with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.
	(c) Prepaid Expenses
	Prepaid expenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, insurance policies and license fees. These advanced payments are amortized to expense either as services are performed or over the relevant service period using the straight line method.
	(d) Property and Equipment
	Property and equipment consist primarily of furnishings, fixtures, leasehold improvements, capital leases and computer equipment and are recorded at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized using the straight-line method over the remaining lease term or the life of the asset, whichever is shorter.
	Description	Estimated Useful Life
	Office equipment and furniture	5 to 7 years
	Leasehold improvements	3 years
	Computer equipment	3 years
	Equipment under capitalized lease	Over life of lease
	(e) Fair Value of Financial Instruments
	The Company measures fair value in accordance with generally accepted accounting principles. Fair value measurements are applied under other accounting pronouncements that require or permit fair value measurements. Financial instruments included in the Company’s balance sheets consist of cash and cash equivalents, accounts payable, accrued expenses, due to related parties, and derivative liability. The carrying amounts of these instruments reasonably approximate their fair values due to their short-term maturities.
	(f) Convertible Debentures and Warrant Liability
	The Company accounts for the convertible debentures and warrants issued in connection with the 2013 Purchase Agreement, the 2012 Purchase Agreement and the 2010 Purchase Agreement (see Note 10) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.
	(g) Concentration of Credit Risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and is insured to the maximum limitations. Balances in these accounts may exceed federally insured limits at times, which expose the Company to institutional risk.
	(h) Research and Development
	Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
	(i) Stock-Based Compensation
	Stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the required service period, which is generally equal to the vesting period. Share-based compensation is recognized only for those awards that are ultimately expected to vest.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model.  The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.
	(j) Basic and Diluted Income/(Loss) per Common Share
	Basic net income/(loss) per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is calculated based on the weighted-average number of shares of common stock and other dilutive securities outstanding during the period. The potential dilutive shares of common stock resulting from the assumed exercise of stock options and warrants are determined under the treasury stock method.
	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income/(loss) per share.
		Year Ended December 31,
		2014		2013
	Numerator:
	Net income/(loss)	$	7,770,767	$	-39,656,975
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share		20,381,554		7,516,223
	Effect of dilutive securities:
	Warrants to purchase common stock		4,428,441		-
	Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share		24,809,995		7,516,223
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.
	As of December 31, 2014 and 2013, potentially dilutive securities include:
		Year Ended December 31,
		2014		2013
	Warrants to purchase common stock		4,455,231		34,181,166
	Options to purchase common stock		-		5,594,151
	Total potentially dilutive securities		4,455,231		39,775,317
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net income/(loss) per share if their effect is anti-dilutive. The aggregate number of common equivalent shares (related to options, warrants and convertible debentures) that have been excluded from the computations of diluted net income/(loss) per common share at December 31, 2014 and 2013 were 50,867,639 and 13,966,897, respectively, as their exercise prices are greater than the fair market price per common share as of December 31, 2014 and 2013, respectively.
	(k) Comprehensive Loss
	The Company has no components of other comprehensive loss other than its net loss, and accordingly, comprehensive loss is equal to net loss for all periods presented.
	(l) Income Taxes
	The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the period in which the differences are expected to affect taxable income. The Company provides a valuation allowance when it appears more likely than not that some or all of the net deferred tax assets will not be realized. The Company has not performed an Internal Revenue Section 382 limitation study. Depending on the outcome of such study, the gross amount of net operating losses recognized in future tax periods could be limited.
	A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded.
	The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2014 and 2013 respectively. In addition, the Company had no amounts accrued for interest and penalties as of December 31, 2014 and 2013, respectively.
	(m) Recently Issued Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The objective of the amendments in this Update is to eliminate requirements for entities which have either not commenced principal operations or have not generated significant revenue from principal operations to present inception-to-date information in the financial statements. In addition, the Update eliminated the exception for evaluating such entities as possible variable interest entities.
	The Company elected to early adopt this guidance as permitted for its financial statements for the year ending December 31, 2014. As a result of adopting this guidance, the Company has retrospectively removed the inception-to-date financial results that have been historically included in the financial statements. Further, the Company has disclosed information about the risks and uncertainties related to the activities in which the Company is currently engaged and information about the intended operations of the Company.
	In August 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements-Going Concern (Topic 205-40)” (“ASU 2014-15”). Under the standard, management is required to evaluate for each annual and interim reporting period whether it is a probable that the entity will not be able to meet its obligations as they become due within one year after the date that financial statements are issued, or are available to be issued, where applicable.  ASU 2014-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for the Company on January 1, 2017. The Company will be evaluating the impact, if any, that the standard will have on its financial condition, results of operations, and disclosures in the near future.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	5. PROPERTY AND EQUIPMENT
	Property and equipment as of December 31, 2014 and 2013 consist of the following:
		2014		2013
	Computer equipment and software	$	17,721	$	17,721
	Office furniture and equipment		72,338		52,242
	Leasehold improvements		8,449		8,449
	Capital leases- equipment		11,500		-
	Total property and equipment		110,008		78,412
	Accumulated depreciation		-79,278		-66,692
	Total property and equipment, net	$	30,730	$	11,720
	Depreciation expense for the years ended December 31, 2014 and 2013 was $12,586 and $13,117, respectively.

INTANGIBLE_ASSETS_AND_INTELLEC

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	6. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY
	License Agreements
	Onapristone License Agreement
	The Company’s rights to onapristone are governed by a license agreement with Invivis Pharmaceuticals, Inc. (“Invivis”), dated February 13, 2012. Under this agreement, the Company holds an exclusive, royalty-bearing license for the rights to commercialize onapristone for all therapeutic uses. The license agreement provides the Company with worldwide rights to develop and commercialize onapristone with the exception of the commercialization rights in France; provided, that the Company has an option to acquire French commercial rights from Invivis upon notice to Invivis together with additional consideration.
	The onapristone license agreement provides the Company with exclusive, worldwide rights to a United States patent application that relates to assays for predictive biomarkers for anti-progestin efficacy. The Company intends to expand its patent portfolio by filing additional patent applications covering the use of onapristone and/or a companion diagnostic product. If the pending patent application issues, the issued patent would be scheduled to expire in 2031.
	The Company made a one-time cash payment of $500,000 to Invivis upon execution of the license agreement on February 13, 2012. Additionally, Invivis will receive performance-based cash payments of up to an aggregate of $15.1 million upon successful completion of clinical and regulatory milestones relating to onapristone, which milestones include the marketing approval of onapristone in multiple indications in the United States or the European Union as well as Japan. The first milestone was due upon the dosing of the first patient in a pharmacokinetic study and was achieved during August 2013 and the Company made a $150,000 payment to Invivis during October 2013. The Company made its next milestone payment of $100,000 to Invivis upon the dosing of the first subject in the first Company-sponsored Phase I clinical trial of onapristone in January 2014. In addition, the Company will pay Invivis low single digit sales royalties based on net sales of onapristone by the Company or any of its sublicensees. Pursuant to a separate services agreement which expired in April 2014, Invivis provided the Company with certain clinical development support services, which includes the assignment of up to two full-time employees to perform such services, in exchange for a monthly cash payment of approximately $70,833. Effective April 1, 2014, the Company renewed the services agreement for a period of one year for a monthly cash payment of $50,000 and certain other performance based milestones.
	Under the license agreement with Invivis, the Company also agreed to indemnify and hold Invivis and its affiliates harmless from any and all claims arising out of or in connection with the production, manufacture, sale, use, lease, consumption or advertisement of onapristone, provided, however, that the Company shall have no obligation to indemnify Invivis for claims that (a) any patent rights infringe third party intellectual property, (b) arise out of the gross negligence or willful misconduct of Invivis, or (c) result from a breach of any representation, warranty confidentiality obligation of Invivis under the license agreement. The license agreement will terminate upon the later of (i) the last to expire valid claim contained in the patent rights, and (ii) February 13, 2032. In general, Invivis may terminate the license agreement at any time upon a material breach by the Company to the extent the Company fails to cure any such breach within 90 days after receiving notice of such breach or in the event the Company files for bankruptcy. The Company may terminate the agreement for any reason upon 90 days’ prior written notice.
	University of Minnesota License
	In February 2014, the Company entered into an Exclusive Patent License Agreement with the Regents of the University of Minnesota (UM) pursuant to which it was granted an exclusive, worldwide, royalty-bearing license for the rights to develop and commercialize technology embodied by certain patent applications relating to a gene expression signature derived from archived breast cancer tissue samples. The Company plans to develop and commercialize this technology as part of the onapristone companion diagnostic development program.
	The license agreement requires Arno to use commercially reasonable efforts to commercialize the licensed technology as soon as practicable, and includes several performance milestones relating to the development and commercialization of the technology to be achieved by specified dates. Under the terms of the agreement, Arno made a small one-time cash payment and reimbursed UM for past patent expenses it has incurred. The agreement also provides that the Company will pay royalties to UM on net sales of “Licensed Products” (as defined in the agreement) at a rate in the low-single digits, which royalty obligation terminates on a licensed product-by-licensed product and country-by-country basis upon the first date when there is no longer a valid claim under a licensed patent or patent application covering such licensed product in the country where the licensed product is made or sold.
	The term of the license agreement continues until the last date on which there is any active licensed patent or pending patent application. UM may terminate the agreement earlier upon a breach by Arno of one or more of its obligations that remains uncured for a period specified in the agreement. UM may also terminate the agreement if Arno voluntarily files for bankruptcy or similar proceeding, or if a petition for an involuntary bankruptcy proceeding is filed and is not released for 60 days. The agreement may be immediately terminated upon notice to the Company if it commences or maintains a proceeding in which it asserts that the licensed patents are invalid or unenforceable. Arno may terminate the agreement at any time and for any reason upon 90 days’ written notice.
	The license agreement further provides that the Company will indemnify and hold UM and its affiliates harmless from any and all suits, actions, claims, liabilities, demands, damages, losses or expenses relating to exercise of the Company’s rights under the agreement, including the right to commercialize the licensed technology. UM is required to indemnify Arno with respect to claims relating to or resulting from its breach of the agreement.
	AR-12 and AR-42 License Agreements
	The Company’s rights to both AR-12 and AR-42 are governed by separate license agreements with The Ohio State University Research Foundation (“Ohio State”) entered into in January 2008. Pursuant to each of these agreements, Ohio State granted the Company exclusive, worldwide, royalty-bearing licenses to commercialize certain patent applications, know-how and improvements relating to AR-12 and AR-42 for all therapeutic uses.
	In 2008, pursuant to the Company’s license agreements for AR-12 and AR-42, the Company made one-time cash payments to Ohio State in the aggregate amount of $450,000 and reimbursed it for past patent expenses. Additionally, the Company is required to make performance-based cash payments upon successful completion of clinical and regulatory milestones relating to AR-12 and AR-42 in the United States, Europe and Japan. The license agreements for AR-12 and AR-42 provide for aggregate potential milestone payments of up to $6.1 million for AR-12, of which $5.0 million is due only after marketing approval in the United States, Europe and Japan, and $5.1 million for AR-42, of which $4.0 million is due only after marketing approval in the United States, Europe and Japan.  In September 2009, the Company paid Ohio State a milestone payment upon the commencement of the first Company-sponsored Phase I clinical study of AR-12.  The first milestone payment for AR-42 will be due when the first patient is dosed in the first Company-sponsored clinical trial, which is not expected to occur in 2015. Pursuant to the license agreements for AR-12 and AR-42, the Company must pay Ohio State royalties on net sales of licensed products at rates in the low-single digits. To the extent the Company enters into a sublicensing agreement relating to either or both of AR-12 or AR-42, the Company will be required to pay Ohio State a portion of all non-royalty income received from such sublicensee. The Company was not required to make any milestone payments during 2014 and does not expect to be required to make any milestone payments under these license agreements during 2015.
	The license agreements with Ohio State further provide that the Company will indemnify Ohio State from any and all claims arising out of the death of or injury to any person or persons or out of any damage to property, or resulting from the production, manufacture, sale, use, lease, consumption or advertisement of either AR-12 or AR-42, except to the extent that any such claim arises out of the gross negligence or willful misconduct of Ohio State. The license agreements for AR-12 and AR-42 each expire on the later of (i) the expiration of the last valid claim contained in any licensed patent and (ii) 20 years after the effective date of the license. Ohio State will generally be able to terminate either license upon the Company’s breach of the terms of the license to the extent the Company fails to cure any such breach within 90 days after receiving notice of such breach or the Company files for bankruptcy. The Company may terminate either license upon 90 days prior written notice.

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
ACCRUED LIABILITIES	7. ACCRUED LIABILITIES
	Accrued liabilities as of December 31, 2014 and 2013 consist of the following:
		2014		2013
	Accrued compensation and related benefits	$	407,497	$	439,156
	Accrued severance		250,605		-
	Accrued research and development expenses		744,240		316,099
	Accrued other expenses		7,951		170,000
		$	1,410,293	$	925,255

CONVERTIBLE_DEBENTURES

CONVERTIBLE DEBENTURES	12 Months Ended
	Dec. 31, 2014
Convertible Notes Payable [Abstract]
CONVERTIBLE DEBENTURES	8. CONVERTIBLE DEBENTURES
	On November 26, 2012, the Company entered into a Securities Purchase Agreement, with a number of institutional and accredited investors (as amended, the “2012 Purchase Agreement”) pursuant to which the Company sold in a private placement an aggregate principal amount of $14,857,200 of three-year 8% Senior Convertible Debentures(“the Debentures”). In accordance with the 2012 Purchase Agreement, the Company also issued five-year Series A warrants to purchase an aggregate of 6,190,500 shares of common stock at an initial exercise price of $4.00 per share (the “Series A Warrants”) and 18-month Series B warrants to purchase an aggregate of 6,190,500 shares of common stock at an initial exercise price of $2.40 per share (the “Series B Warrants” and together with the Series A Warrants, the “2012 Warrants”). The sale of the Debentures and 2012 Warrants, which occurred in two closings on November 26, 2012 and December 18, 2012, resulted in aggregate gross proceeds of approximately $14.9 million, before deducting placement agent fees and other transaction-related expenses of approximately $1.2 million. The 2012 Warrants were valued at $12,430,524 on issuance and recorded as a debt discount.
	The conversion price of the Debentures was subject to a “full-ratchet” anti-dilution provision, such that in the event the Company makes an issuance of common stock (subject to customary exceptions) at a price per share less than the applicable exercise price of the Debentures, the applicable conversion price will be reduced to the price per share applicable to such new issuance. However, after such time as the Company has raised at least $12 million in subsequent equity financings, the conversion price of the Debentures will be subject to a customary weighted-average price adjustment with respect to new issuances. This conversion feature of the Debentures is considered an embedded derivative and was accounted for separately from the Debentures and was valued at $7,548,500 on issuance and recorded as a debt discount.
	The following table reflects the debt discount for the 2012 Warrants and the embedded conversion feature of the Debentures at their fair values on issuance:
		Issuance
	Debentures, principal		14,857,200
	2012 Warrant liability		-12,430,524
	Debenture conversion feature		-7,548,500
			-5,121,824
	The excess fair value over proceeds on the date of issuance of approximately $5.1 million was recorded in interest expense on the statement of operations on the issuance. As of December 31, 2014 and December 31, 2013, the Company recorded amortization on the debt discount of approximately $0.0 million and $14.9 million, respectively, to interest expense. As a result of the Conversion Agreement, as discussed below, the Company accelerated the amortization of the remaining balance of debt discount of approximately $10.6 million on October 29, 2013 as the underlying debentures converted into common shares.
	On October 29, 2013, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Holders”) of its Debentures. Pursuant to the Conversion Agreement, the Holders agreed to convert the entire outstanding principal amount of their Debentures, together with accrued and unpaid interest through October 29, 2013, into shares of the Company’s common stock at a conversion price of $2.40 per share for a total of approximately 6,530,154 shares, of which 345,606 shares were issued for the accrued and unpaid interest. As a result of such conversion, all of the Company’s obligations under the Debentures are fully satisfied.
	As additional consideration for their agreement to convert the Debentures, the Company provided each Holder with one year of additional accrued interest at 8% per annum at conversion and extended the term of the Series B Warrants issued to the Holders in connection with their initial purchase of the Debentures to October 31, 2014. The additional year of accrued interest was satisfied by the issuance of shares of common stock at a price of $2.40 per share for a total additional issuance of approximately 494,764 shares of common stock. The Company recorded the inducement to convert the debentures as additional interest expense in the amount of approximately $1,187,433.
	Pursuant to the terms of a Registration Rights Agreement entered into on November 26, 2012 in connection with the 2012 Purchase Agreement, the Company agreed to file a registration statement under the Securities Act of 1933, as amended, covering the resale of: (i) 100% of the shares of common stock issuable as payment of accrued interest under the Debentures and upon exercise of the Series A Warrants; and (ii) 150% of the shares of common stock issuable upon conversion of the Debentures and upon exercise of the Series B Warrants (collectively, the “Registrable Securities”). The Company further agreed to cause such registration statement to be filed within 30 days following the date of the Registration Rights Agreement, or by December 26, 2012, and to cause such registration statement to be declared effective within 60 days following the date of the Registration Rights Agreement, or by January 25, 2013, or, if the registration statement was subject to review by the SEC, to cause such registration statement to be declared effective within 120 days following the date of the Registration Rights Agreement, or by March 26, 2013. If such registration statement, covering 100% of the Registrable Securities, was not declared effective by the SEC by the applicable date, the Company agreed to pay liquidated damages to the investors in the amount of 2% of each investor’s aggregate investment amount per month until the registration statement is declared effective or until such earlier time as the Registrable Securities may be traded pursuant to Rule 144.
	On December 26, 2012, the Company filed a registration statement seeking to register 100% of the Registrable Securities. However, the SEC determined that the number of shares the Company was seeking to register exceeded the limitations imposed by the SEC under Rule 415, and the Company was thus unable to register a significant amount of the Registrable Securities. As a result of the SEC’s determination, the Company amended the registration statement to reduce the number of Registrable Securities covered thereby by including only the shares issuable upon exercise of the Series B Warrants. As amended, the registration statement was declared effective by the SEC on April 18, 2013. Accordingly, because a registration statement covering 100% of the Registrable Securities was not declared effective by March 26, 2013, the investors each became entitled to liquidated damages in the amount of 2% of their investment amount per month, payable on March 27, 2013 and on each monthly anniversary thereafter until the Registrable Securities may be traded pursuant to Rule 144. Because the Registrable Securities could be resold by their holders under Rule 144 six months after the applicable closing date under the 2012 Purchase Agreement, the Company was required to pay the investors approximately three months’ of liquidated damages, or approximately $0.9 million in the aggregate.
	On March 25, 2013, the Company and holders of approximately 80% of the principal amount of Debentures entered into an amendment to the Registration Rights Agreement, permitting the Company, in its sole discretion, to elect to pay liquidated damages resulting from the Company’s failure to successfully cause the registration statement covering the resale of 100% of the Registrable Securities to be declared effective by the SEC by March 26, 2013, by issuing shares of common stock in lieu of cash. If electing to issue shares in lieu of paying cash, the Company agreed to issue to each investor a number of shares of common stock equal to (a) the aggregate amount of liquidated damages that the Company is electing to pay to such investor in the form of shares, divided by (b) $2.40. Pursuant to the terms of the Registration Rights Agreement, because holders of over two-thirds of the Debentures consented in writing to the March 25, 2013 amendment, such amendment is binding on all holders of Registrable Securities. On March 27, 2013, in accordance with the amendment to the Registration Rights
	Agreement, the Company issued shares of common stock to the investors in lieu of an aggregate cash payment of $297,148, representing the first installment of liquidated damages under the Registration Rights Agreement, as amended. On April 29, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued additional shares of common stock to the investors in lieu of an aggregate cash payment of $327,688, representing the second installment of liquidated damages under the Registration Rights Agreement, as amended.
	In May 2013, the Company determined that investors were entitled to additional liquidated damages arising from the 2012 Purchase Agreement in the amount of $288,674.  The Company assessed that this amount should have been accrued in 2012 as part of the issuance. The Company determined that the impact of not reflecting this in 2012 was not material to the 2012 financial statements and has reflected this as interest expense in the first quarter of 2013.  This expense resulted in the issuance of additional shares and a non-cash charge in 2013. On May 27, 2013, the Company issued shares of common stock to the investors in lieu of an aggregate cash payment of $288,674, representing the third and final installment of liquidated damages under the Registration Rights Agreement, as amended. The aggregate number of shares issued in lieu of cash payments for liquidated damages under the Debentures was 380,606 shares of common stock.
	In March 2013, the Company sought the agreement of the Debenture holders to amend their respective Debentures to provide for the accrual of all interest payments under such Debentures until the applicable maturity date in November or December of 2015, with such interest accruing at the rate of 8% per annum, compounding quarterly. As of October 29, 2013, the date of the Conversion Agreement, the Company had entered into such amendments with the holders of Debentures in the aggregate principal amount of $12,230,000. In connection with the Conversion Agreement, all of the accrued interest on the Debentures were converted into 345,606 shares of common stock.
	The following table illustrates the components of total interest expense for 2014 and 2013 incurred under the Debentures.
		Year Ended December 31,
	Interest Expense	2014		2013
	Note conversion discount	$	—	$	14,366,161
	Interest expense on 2012 debentures		—		2,174,244
	Amortized deferred financing fees		—		1,709,531
	Liquidated damages on 2012 debentures		—		319,221
	Total Interest Expense	$	—	$	18,569,157

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	9. FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company defines fair value as the amount at which an asset (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The fair value estimates presented in the table below are based on information available to the Company as of December 31, 2014.
	The accounting standard regarding fair value measurements discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
		•	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
		•	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
		•	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2014:
						Quoted Market
						Prices in Active			Significant Other		Significant Other
			Fair Value			Markets			Observable Inputs		Unobservable Inputs
			Dec 31, 2014			(Level 1)			(Level 2)		(Level 3)
	Liabilities:
	Warrant liability - 2010 Series B		$	28,066		$	-		$	-	$	28,066
	Warrant liability - 2012 Series A&B			3,520,319			-			-		3,520,319
	Warrant liability - 2012 placement agent			67,246			-			-		67,246
	Warrant liability - 2013 Series D&E			3,036,986			-			-		3,036,986
	Warrant liability - 2013 placement agent			18,907			-			-		18,907
	Total		$	6,671,524		$	-		$	-	$	6,671,524
	The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2013:
						Quoted Market
						Prices in Active			Significant Other		Significant Other
			Fair Value			Markets			Observable Inputs		Unobservable Inputs
			December 31, 2013			(Level 1)			(Level 2)		(Level 3)
	Liabilities:
	Warrant liability - 2010 Series B		$	362,452		$	-		$	-	$	362,452
	Warrant liability - 2012 Series A&B			16,703,983			-			-		16,703,983
	Warrant liability - 2012 placement agent			362,633			-			-		362,633
	Warrant liability - 2013 Series D&E			18,337,733			-			-		18,337,733
	Warrant liability - 2013 placement agent			98,080			-			-		98,080
	Total		$	35,864,881		$	-		$	-	$	35,864,881
	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held at December 31, 2014:
	Fair Value Measurement Using Significant Unobservable Inputs (Level 3)
			Total								2013						2012				Debenture
			Warrant			2013			2013		Placement		2012		2012		Placement		2010		Conversion
			Liability			Series E			Series D		Agent		Series B		Series A		Agent		Series B		Feature
	Balance at January 1, 2013		$	21,420,276		$	-		$	-	$	-	$	5,744,784	$	6,685,740	$	542,530	$	898,722	$	7,548,500
	Purchase, sales and settlements:
	Warrants and other derivatives issued			15,681,151			5,057,354			10,552,240		71,557
	Settlement of derivatives			-5,403,000																		-5,403,000
	Total gains or losses:
	Unrealized depreciation/(appreciation)			4,166,454			797,852			1,930,287		26,523		-2,928,108		7,201,567		-179,897		-536,270		-2,145,500
	Balance at January 1, 2014		$	35,864,881		$	5,855,206		$	12,482,527	$	98,080	$	2,816,676	$	13,887,307	$	362,633	$	362,452	$	-
	Purchase, sales and settlements:
	Warrants and other derivatives issued
	Settlement of derivatives
	Total gains or losses:
	Unrealized depreciation/(appreciation)			-29,193,357			-5,829,469			-9,471,278		-79,173		-2,804,295		-10,379,369		-295,387		-334,386
	Balance at Dec 31, 2014		$	6,671,524		$	25,737		$	3,011,249	$	18,907	$	12,381	$	3,507,938	$	67,246	$	28,066	$	-
	Value per Warrant		$	0.154		$	0.002		$	0.234	$	0.288	$	0.002	$	0.34	$	0.237	$	0.035
	Significant assumptions used at December 31, 2014 and 2013 for the warrants and embedded conversion discount derivative liability of the Debentures are as follows:
			December 31, 2014			December 31, 2013
	Volatility			173	%		108	%
	Risk-free interest rate			1.65	%		2.08	%

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	10. STOCKHOLDERS’ EQUITY
	Common Stock
	The Company amended its Amended & Restated Certificate of Incorporation to effect a combination of its common stock at a ratio of 1-for-8 as of October 29, 2013 (the “Reverse Split”). The Reverse Split was effective immediately prior to the entry into the 2013 Purchase Agreement described below. The Reverse Split was authorized by the stockholders of the Company on November 10, 2010.
	As a result of the Reverse Split, all references to common stock, stock options and warrants and other securities convertible into common stock, and per share amounts for all prior periods presented have been retroactively restated to reflect the 1-for-8 reverse stock split of common stock.
	On March 27, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued an aggregate of approximately 123,809 shares of common stock to the investors in lieu of an aggregate cash payment of $297,144, representing the first installment of liquidated damages under the Registration Rights Agreement, as amended.
	On April 29, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued an aggregate of approximately 136,536 shares of common stock to the investors in lieu of an aggregate cash payment of $327,688, representing the second installment of liquidated damages under the Registration Rights Agreement, as amended.
	On May 27, 2013, in accordance with the amendment to the Registration Rights Agreement, the Company issued an aggregate of approximately 120,280 shares of common stock to the investors in lieu of an aggregate cash payment of $288,674, representing the third and final installment of liquidated damages under the Registration Rights Agreement, as amended.
	On October 29, 2013, the Company entered into a Securities Purchase Agreement (the “2013 Purchase Agreement”) with certain purchasers identified therein (the “Purchasers”) pursuant to which the Company sold and the Purchasers purchased, an aggregate of 12,868,585 units of the Company’s securities (the “Units”), with each Unit consisting of the following:
		(i)	either (a) one share of common stock (each a “Share,” and collectively, the “Shares”), or (b) a five-year common stock warrant to purchase one share of common stock (collectively, the “Series C Warrant Shares”) at an exercise price of $0.01 per share (collectively, the “Series C Warrants”);
		(ii)	a five-year warrant to purchase one share of common stock (collectively, the “Series D Warrant Shares”) at an exercise price of $4.00 per share (collectively, the “Series D Warrants”); and
		(iii)	a warrant, expiring on October 31, 2014, to purchase one share of common stock (collectively, the “Series E Warrant Shares,” and together with the Series C Warrant Shares and the Series D Warrant Shares, the “Warrant Shares”) at an exercise price of $2.40 per share (collectively, the “Series E Warrants,” and together with the Series C Warrants and the Series D Warrants, the “2013 Warrants”).
	The Company sold and issued 8,413,354 Units consisting of Shares, Series D Warrants and Series E Warrants at a purchase price of $2.40 per Unit, and 4,455,231 Units consisting of Series C Warrants, Series D Warrants and Series E Warrants at a purchase price of $2.39 per Unit, for total gross proceeds to the Company of $30.84 million, before deducting fees and other transaction related expenses of approximately $760,000. A closing of the sale of 12,826,752 Units was completed on October 29, 2013, and the sale of the remaining 41,833 Units was completed on October 30, 2013.
	As of December 31, 2014, the Company had 20,408,616 shares of common stock issued and outstanding and approximately 55,322,870 shares of common stock reserved for issuance upon the exercise of outstanding options and warrants.
	The Purchase Agreement contains customary representations, warranties and covenants by each of the Company and the Purchasers. In addition, the Purchase Agreement provides that each Purchaser has a right, subject to certain exceptions described in the agreement, to participate in future issuances of equity and debt securities by the Company for a period of 18 months following the effective date of the Registration Statement (defined below).
	Contemporaneously with the entry into the Purchase Agreement, and as contemplated thereby, the Company entered into a Registration Rights Agreement with the Purchasers. Pursuant to the terms of the Registration Rights Agreement, the Company agreed to file, on or before December 30, 2013 (the “Filing Date”), a registration statement under the Securities Act covering the resale of the Shares and Warrant Shares (the “Registration Statement”), and to cause such Registration Statement to be declared effective by the Commission as soon as practicable thereafter, but not later than 120 days following the date of the Registration Rights Agreement (the “Effectiveness Date”). The Registration Statement was declared effective on January 27, 2014. The Company is required to maintain the effectiveness of the Registration Statement until all of the shares covered thereby are sold or may be sold pursuant to Rule 144 under the Securities Act without volume or manner of sale restrictions and without the requirement that the Company be in compliance with the current public information requirements of Rule 144.
	Warrants
	In accordance with the 2010 sale and issuance of Series A preferred stock, the Company issued two-and-one-half-year “Class A” warrants to purchase an aggregate of 152,740 shares of Series A Preferred Stock at an initial exercise price of $8.00 per share (the “2010 Class A Warrants”) and five-year Class B warrants to purchase an aggregate of 801,885 shares of Series A Preferred Stock at an initial exercise price of $9.20 per share, the “2010 Class B Warrants,” and together with the 2010 Class A Warrants, the “2010 Warrants”). Upon the automatic conversion of the Series A Preferred Stock in January 2011, the 2010 Warrants automatically converted to the right to purchase an equal number of shares of common stock. The terms of the warrants contain an anti-dilutive price adjustment provision, such that, in the event the Company issues common shares at a price below the current exercise price of the 2010 Warrants, the exercise price will be decreased pursuant to a customary “weighted-average” formula. In accordance with this provision and as a result of the issuances made pursuant to the 2012 Purchase Agreement and 2013 Purchase Agreement, the exercise price of the 2010 Class B warrants has been adjusted to $3.55 per share. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used.  Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $0.0 million and approximately $0.4 million at December 31, 2014 and December 31, 2013, respectively. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error. This valuation is revised on a quarterly basis until the warrants are exercised or they expire with the changes in fair value recorded in other income (expense) on the statement of operations. The 2010 Class A warrants, representing the right to purchase an aggregate of 152,704 shares of common stock, expired unexercised during the year ended December 31, 2013.
	Pursuant to the 2012 Purchase Agreement, the Company issued five-year Series A warrants to purchase an aggregate of approximately 6,190,500 shares of common stock at an initial exercise price of $4.00 per share and 18-month Series B warrants to purchase an aggregate of approximately 6,190,500 shares of common stock at an initial exercise price of $2.40 per share. On October 28, 2014, the warrant holders were notified that the expiration date of the Series B Warrants had been extended until December 31, 2014. On December 31, 2014, warrant holders were notified that the expiration date for the Series B Warrants was further extended to January 31, 2015. The terms of the 2012 Warrants contain a “full-ratchet” anti-dilutive price adjustment provision. In accordance with such full-ratchet anti-dilution provision, in the event that the Company sells or issues additional shares of common stock, including securities convertible or exchangeable for common stock (subject to customary exceptions), at a per share price less than the applicable 2012 Warrant exercise price, such warrant exercise price will be reduced to an amount equal to the issuance price of such subsequently issued shares; after such time as the Company has raised at least $12 million in additional equity financing, the 2012 Warrants are subject to further anti-dilution protection based on a weighted-average formula. Further, the anti-dilution provisions of the 2012 Warrants provide that, in addition to a reduction in the applicable exercise price, the number of shares purchasable thereunder is increased such that the aggregate exercise price of the warrants (exercise price per share multiplied by total number of shares underlying the warrants) remained unchanged. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used.  Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $3.5 million and $16.7 million at December 31, 2014 and December 31, 2013, respectively.
	In connection with the 2012 offering of the Debentures and 2012 Warrants, the Company engaged Maxim Group LLC, or Maxim Group, to serve as placement agent. In consideration for its services, the Company paid Maxim Group a placement fee of $1,035,000. In addition, the Company issued to Maxim Partners LLC, or Maxim Partners, an affiliate of Maxim Group, 7,500 shares of common stock and five-year warrants to purchase an additional 283,750 shares of common stock at an initial exercise price of $2.64 per share. The warrants issued to Maxim Partners are in substantially the same form as the Warrants issued to the investors, except that they do not include certain anti-dilution provisions contained in the Warrants. However, the placement warrants do contain a provision that could require the Company to repurchase the warrants from the holder under certain conditions. Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $0.1 million and $0.4 million at December 31, 2014 and December 31, 2013, respectively.
	Under the terms of the 2013 Purchase Agreement, each Purchaser had the option to elect to receive a Series C Warrant in lieu of a Share in connection with each Unit it purchased. The Series C Warrants have a five-year term and are exercisable at an initial exercise price of $0.01 per share. The Series D Warrants have a five-year term and are exercisable at an initial exercise price of $4.00 per share, subject to adjustment for stock splits, combinations, recapitalization events and certain dilutive issuances (as described below). The Series E Warrants were initially exercisable until October 31, 2014 at an initial exercise price of $2.40 per share, subject to adjustment for stock splits, combinations, recapitalization events and certain dilutive issuances (as described below). On October 28, 2014, the warrant holders were notified that the expiration date of the Series E Warrants had been extended until December 31, 2014. On December 31, 2014, warrant holders were notified that the expiration date for the Series E Warrants was further extended to January 31, 2015. The applicable exercise price of the Series D Warrants and Series E Warrants (but not the Series C Warrants) is subject to a weighted-average price adjustment in the event the Company makes future issuances of common stock or rights to acquire common stock (subject to certain exceptions) at a per share price less than the applicable warrant exercise price. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used.  Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability for the Series D and Series E Warrants to be approximately $3.0 million and $18.3 million at December 31, 2014 and December 31, 2013.
	The 2013 Warrants are required to be exercised for cash, provided that if during the term of the warrants there is not an effective registration statement under the Securities Act covering the resale of the shares issuable upon exercise of the warrants, then the warrants may be exercised on a cashless (net exercise) basis.
	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of December 31, 2014.
	Grant Date		Warrants		Exercise		Weighted		Expiration		Exercised		Warrants
			Issued		Price		Average		Date				Outstanding
							Exercise
							Price
	9/3/10			801,885	$	3.55	$	3.55		9/3/15		-		801,885
	9/3/10			132,116	$	8.8	$	8.8		9/3/15		-		132,116
	11/26/12			5,293,738	$	2.4	$	2.4		1/31/15		-		5,293,738
	12/18/12			896,748	$	2.4	$	2.4		1/31/15		-		896,748
	11/26/12			8,822,887	$	2.4	$	2.4		11/26/17		-		8,822,887
	11/26/12			261,250	$	2.64	$	2.64		11/26/17		-		261,250
	12/18/12			1,494,577	$	2.4	$	2.4		12/18/17		-		1,494,577
	12/18/12			22,500	$	2.64	$	2.64		12/18/17		-		22,500
	10/29/13			4,455,231	$	0.01	$	0.01		10/29/18		-		4,455,231
	10/29/13			12,868,585	$	2.4	$	2.4		1/31/15		-		12,868,585
	10/29/13			12,868,585	$	4	$	4		10/29/18		-		12,868,585
	10/29/13			65,650	$	2.64	$	2.64		10/29/18		-		65,650
				47,983,752			$	2.65				-		47,983,752

STOCK_OPTION_PLAN

STOCK OPTION PLAN	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK OPTION PLAN	11. STOCK OPTION PLAN
	The Company’s 2005 Stock Option Plan (the “Plan”) was originally adopted by the Board of Directors of Old Arno in August 2005, and was assumed by the Company on June 3, 2008 in connection with the Merger. After giving effect to the Merger, there were initially 373,831 shares of the Company’s common stock reserved for issuance under the Plan. On April 25, 2011, the Company’s Board of Directors (the “Board”) approved an amendment to the Plan to increase the number of shares of common stock issuable under the Plan to 875,000 shares. On January 14, 2013, the Company’s Board of Directors approved an amendment to the Plan to increase the number of shares of common stock issuable under the Plan to 945,276 shares. On October 7, 2013, the Company’s Board of Directors adopted an amendment to the Company’s 2005 Plan, as amended that increased the number of shares of common stock authorized for issuance thereunder from 945,276 to 11,155,295. Under the Plan, incentives may be granted to officers, employees, directors, consultants, and advisors. Incentives under the Plan may be granted in any one or a combination of the following forms: (a) incentive stock options and non-statutory stock options, (b) stock appreciation rights, (c) stock awards, (d) restricted stock and (e) performance shares.
	The Plan is administered by the Board, or a committee appointed by the Board, which determines recipients and types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The term of stock options granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than the fair market value of the Company’s common stock on the grant date, and generally vest over a period of three to four years.
	As of December 31, 2014, there are 3,776,197 shares available for future grants and awards under the Plan, which covers stock options, warrants and restricted awards.
	On October 7, 2013, the Board approved a plan to grant 10-year stock options under the 2005 Plan to each of Glenn Mattes, the Company’s President and Chief Executive Officer, Alexander Zukiwski, M.D., the Company’s Chief Medical Officer, and Stefan Proniuk, Ph.D., the Company’s Vice President, Product Development, to purchase 5.5%, 4.5% and 0.65%, respectively, of the number of shares issued by the Company upon the conversion of the Debentures (the “Management Options”). The effective grant date of the Management Options was November 4, 2013, following the complete conversion of the Debentures pursuant to the Conversion Agreement, and the exercise price was fixed at $2.40 per share, reflecting the fair market value of the common stock. The total number of shares subject to the Management Options granted to Mr. Mattes, Dr. Zukiwski and Dr. Proniuk was 386,697, 316,389 and 45,701 shares, respectively. The right to purchase the shares subject to the Management Options will vest in 36 equal monthly installments commencing on the first month anniversary of the date of grant and continuing each month thereafter until fully vested, provided that such vesting shall accelerate upon a “change of control” of the Company, as such term is defined under the 2005 Plan (but excluding any transaction conducted primarily for purposes of raising capital).
	On October 7, 2013, the Board also adopted a standard compensation plan applicable to its non-employee directors (the “Director Compensation Plan”), pursuant to which the Company’s non-employee directors are entitled to cash and equity-based compensation for their services as directors of the Company. Further, on November 4, 2013, and in accordance with the Director Compensation Plan, the Board granted to each non-employee director, 10-year stock options under the 2005 Plan to purchase, at an exercise price of $2.40 per share, a number of shares of Common Stock equal to 0.10% of the then outstanding shares of Common Stock determined on a fully-diluted basis (i.e., assuming the issuance of all shares issuable upon the exercise or conversion of the Company’s outstanding options, warrants or other rights to acquire Common Stock, but excluding all shares reserved for issuance under the 2005 Plan (“Fully-Diluted Basis”)); provided, that the Company’s Chairman of the Board shall instead be granted a stock option to purchase 0.20% of the outstanding shares of Common Stock determined on a Fully-Diluted Basis (collectively the “Director Options”).
	In addition to the Director Options, on November 4, 2013, the Board made one-time grants of 10-year stock options to Arie Belldegrun, M.D., the Company’s Chairman of the Board, and Steven Ruchefsky, to purchase a number of shares of Common Stock equal to 5.0% and 0.2%, respectively, of the shares of Common Stock outstanding on the effective date of such grant, determined on a Fully-Diluted Basis. Such options are subject to the same terms and conditions applicable to the Director Options.
	During the years ended December 31, 2014 and December 31, 2013 the Company issued the following stock options:
			Year Ended December 31,
			2014			2013
	Options granted			2,423,742			5,038,605
	The Company estimated the fair value of each option award granted using the Black-Scholes option-pricing model. The following assumptions were used for the years ended December 31, 2014 and 2013:
			Year Ended December 31,
			2014			2013
	Expected volatility			86% - 92%			89% - 96%
	Expected term			6 years			4-6 years
	Dividend yield			0.00%			0.00%
	Risk- free interest rate			1.57% - 1.63%			0.77% - 1.35%
	Stock price			$0.85 - $2.90			$2.40
	Forfeiture rate			0.00%			0.00%
	A summary of the status of the options issued under the Plan at December 31, 2014, and information with respect to the changes in options outstanding is as follows:
			Number of			Weighted-			Aggregate
			Shares			Average			Intrinsic
						Exercise			Value
						Price
	Options outstanding at December 31, 2013			5,758,463		$	2.66		$	-
	Granted			2,423,742		$	2.66			-
	Exercised			-			-			-
	Cancelled			-843,087		$	3.23			-
	Options outstanding at December 31, 2014			7,339,118		$	2.59		$	-
	Options vested and expected to vest at December 31, 2014			7,339,118		$	2.59		$	-
	Exercisable at December 31, 2014			2,741,476		$	2.81		$	-
	Shares available for grant under the 2005 Plan			3,776,197
	The following table summarizes information about stock options outstanding at December 31, 2014:
				Outstanding								Exercisable
	Exercise Price			Number of			Weighted-			Weighted-		Number of		Weighted-
				Shares			Average			Average		Shares		Average
							Remaining			Exercise				Exercise Price
							Contractual			Price
							Life (Years)
	$	0.85			136,785			9.84		$	0.85		3,799	$	0.85
	$	1.3			100,000			9.77		$	1.3		-	$	1.3
	$	2.23			223,445			9.15		$	2.23		-	$	2.23
	$	2.4			5,227,589			8.19		$	2.4		2,387,170	$	2.4
	$	2.9			1,548,916			9.07		$	2.9		248,124	$	2.9
	$	8			65,000			5.57		$	8		65,000	$	8
	$	19.38			37,383			3.28		$	19.38		37,383	$	19.38
	Total				7,339,118			8.41		$	2.59		2,741,476	$	2.81
	Stock-based compensation costs under the Plan for the year ended December 31, 2014 and 2013 are as follows:
			Year ended December 31,
			2014			2013
	Research and development		$	979,792		$	572,741
	General and administrative			3,543,876			884,035
	Total		$	4,523,668		$	1,456,776
	The fair value of options vested under the Plan was approximately $3,828,561 and $1,507,982 for the years ended December 31, 2014 and 2013, respectively.
	At December 31, 2014, total unrecognized estimated compensation cost related to stock options granted prior to that date was approximately $8,436,724 which is expected to be recognized over a weighted-average vesting period of 2.8 years. This unrecognized estimated employee compensation cost does not include any estimate for forfeitures of performance-based stock options.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model and is expensed as the underlying options vest. The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.

RELATED_PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTIES	12. RELATED PARTIES
	On June 1, 2009, the Company entered into a services agreement with Two River Consulting, LLC (“TRC”) to provide various clinical development, operational, managerial, accounting and financial, and administrative services to the Company for a period of one year. David M. Tanen, a director and Secretary of the Company and at the time also its President, Arie S. Belldegrun, M.D., the Chairman of the Board of Directors, and Joshua A. Kazam, a director until September 2010, are each partners of TRC. The terms of the Services Agreement were reviewed and approved by a special committee of the Company’s Board of Directors consisting of independent directors. None of the members of the special committee has any interest in TRC or the services agreement. As compensation for the services contemplated by the services agreement, the Company paid TRC a monthly cash fee of $55,000.   The services agreement with TRC expired on April 1, 2011 and from that point until December 31, 2013, TRC billed the Company for actual hours worked on a monthly basis.  For the year ended December 31, 2013, TRC billed the Company $309,330. As of January 1, 2014, the Company is no longer receiving services from TRC.
	On occasion, some of the Company’s expenses were paid by TRC. No interest was charged by TRC on any outstanding balance owed by the Company. For the year ended December 31, 2013 services and reimbursed expenses totaled $347,927. As of December 31, 2013, the Company had a payable to TRC of $26,039, which was paid in full during February 2014.
	The financial condition and results of operations of the Company, as reported, are not necessarily indicative of results that would have been reported had the Company operated completely independently.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	13. INCOME TAXES
	The Company accounts for income taxes using the liability method, which requires the determination of deferred tax assets and liabilities, based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which differences are expected to reverse. The net deferred tax asset is adjusted by a valuation allowance, if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized. The income tax returns of the Company are subject to examination by federal and state taxing authorities. Such examination could result in adjustments to net income or loss, which changes could affect the income tax liabilities of the Company. The Company’s tax returns are open for inspection for all tax years from 2009 to present.
	The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2014 and 2013 and, as of December 31, 2014 and 2013, had no amounts accrued for interest and penalties.
	At December 31, 2014, the Company has recorded no Federal income tax expense or benefit. At December 31, 2014 and 2013, the Company has Federal tax net operating loss carry-forwards of approximately $75.7 and $53.3 million, respectively. The Federal net operating loss carry-forwards will begin to expire  in 2026, unless previously utilized.
	Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets at December 31, 2014 and 2013 are shown below.
		For Year Ended December 31,
		2014			2013
	Non-current deferred tax assets:
	Net operating loss carry forwards	$	30,133,600		$	22,489,800
	Research tax credit		3,267,000			2,873,000
	Accrued expenses		267,000			-
	Stock based compensation		2,451,000			437,000
	Total deferred tax assets		36,118,600			25,799,800
	Non-current deferred tax liability:
	Bonus Section 401 adjustment		-61,000			-91,000
	Depreciation and amortization		-			-5,000
	Total net deferred tax assets		36.057.600			25,703,800
	Valuation allowance		-36,057,600			-25,703,800
	Net deferred tax assets	$	-		$	-
	The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2014 and 2013 the Company recorded valuation allowances of $36.1 million and $25.7 million, respectively, representing a change in the valuation allowance of $10.4 million for the previous fiscal year-ends, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years.
	A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2014 and 2013 are as follows:
		2014			2013
	Federal Tax		34	%		34	%
	State Tax		6.6	%		5.9	%
	Interest Expense		-152.5	%		-
	Incentive stock options		-			3.6	%
	R&D credit		-6.8	%		2.7	%
	Other adjustments		-14.6	%		-
	Valuation allowance/other		133.3	%		-46.2	%
	Net		-			-
	There was no income tax benefit recorded for the years ended December 31, 2014 and 2013.

LEASES_COMMITMENTS_AND_CONTING

LEASES, COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
LEASES, COMMITMENTS AND CONTINGENCIES	14. LEASES, COMMITMENTS AND CONTINGENCIES
	On August 4, 2011, the Company entered into a lease for office space of approximately 4,168 square feet in Flemington, New Jersey (the “Flemington Lease”). The lease commencement date was November 17, 2011, with lease payments beginning in February 2012.  The lease expiration date is three years from the rent commencement date.  The Company provided a cash security deposit of $10,455, or two months’ base rent.  On June 17, 2014, the Company entered into an amendment to the lease extending expiration until January 31, 2018. The Company is also responsible for payment of its share of common area maintenance costs and taxes. The aggregate remaining minimum future payments under the Flemington Lease at December 31, 2014 are approximately $199,386 including common area maintenance charges and taxes. The Flemington Lease contains a three-month free rent period and annual escalations, as such, the Company accounts for rent expense on a straight-line basis. The Company recognized $84,833 and $81,081 in rent expense for the Flemington Lease for the years ended December 31, 2014 and 2013, respectively.
	Future minimum lease payments under operating leases as of December 31, 2014 are as follows:
	2015	$	62,885
	2016		64,430
	2017		66,514
	2018		5,557
	Total future minimum lease payments	$	199,386
	On November 19, 2014, the Company entered into a lease for office equipment. The lease commencement date was November 25, 2014, with lease payments beginning in December 2014.  The lease has an initial term of three years and cannot be cancelled or terminated prior to the end of the initial lease term. After the end of the initial term the company can either enter into a new lease, purchase the equipment or return the equipment. The office equipment lease is classified as a capital lease.
	Future minimum lease payments under capital leases together with the present value of the net minimum lease payments as of December 31, 2014 are as follows;
	2015	$	4,778
	2016		4,778
	2017		4,380
	Total net future minimum lease payments		13,936
	Less: Amount representing interest		-2,691
	Present value of net minimum lease payments	$	11,245
	On October 29, 2013, in connection with the entry into the 2013 Purchase Agreement, the Company entered into an agreement (the “OPKO Agreement”) with OPKO Health, Inc. (“OPKO”) and Frost Group, LLC (“Frost Group”). Under the terms of the OPKO Agreement, as an inducement to the participation by OPKO and Frost Group (or its affiliates and associates) in the purchase and sale of the Units under the Purchase Agreement, the Company granted OPKO with the following rights, so long as OPKO continues to hold at least 3% of the total number of outstanding shares of the Company’s common stock, determined on a fully-diluted basis (i.e., assuming the issuance of all shares underlying outstanding options, warrants and other rights to acquire common stock): (1) OPKO shall have the right to appoint a non-voting observer to attend all meetings of the Company’s Board of Directors, provided that such appointee enters into a confidentiality agreement with the Company and shall be subject to all applicable Company policies; and (2) OPKO shall have a right of first negotiation that provides it with exclusive rights to negotiate with the company for a 45-day period regarding any potential strategic transactions that the Company’s Board of Directors elects to pursue.
	The Company has entered into various contracts with third parties in connection with the development of the licensed technology described in Note 6.
	The aggregate minimum commitment under these contracts as of December 31, 2014 is approximately $7.3 million, all expected to be due during 2015 and 2016.
	In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of December 31, 2014. The Company does not anticipate recognizing any significant losses relating to these arrangements.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	15. SUBSEQUENT EVENTS
	In connection with the 2012 private placement of convertible debentures and warrants and the 2013 private placement of common stock and warrants, the Company issued 2012 Series B Common Stock Purchase Warrants (the “Series B Warrants”) to purchase an aggregate of approximately 6.2 million shares of common stock and 2013 Series E Common Stock Purchase Warrants (the “Series E Warrants”) to purchase an aggregate of approximately 12.8 million shares of common stock. Both the Series B Warrants and Series E Warrants were to expire October 31, 2014. On October 28, 2014, the Company notified the holders of the Series B and E Warrants that the termination date of such warrants had been extended to December 31, 2014, and on December 31, 2014 the warrant holders were notified that the termination dates were further extended to January 31, 2015. Both the Series B Warrants and the Series E Warrants were exercisable at a per share price of $2.40. All of the Series B Warrants and Series E Warrants expired unexercised on January 31, 2015.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates	(a) Use of Estimates
	The preparation of financial statements in conformity with GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees, directors and consultants, valuation of derivatives and estimates of the probability and potential magnitude of contingent liabilities. Actual results could differ from those estimates.
Cash and cash equivalents	(b) Cash and Cash Equivalents
	The Company considers all highly liquid investments with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.
Prepaid Expenses	(c) Prepaid Expenses
	Prepaid expenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, insurance policies and license fees. These advanced payments are amortized to expense either as services are performed or over the relevant service period using the straight line method.
Property and Equipment	(d) Property and Equipment
	Property and equipment consist primarily of furnishings, fixtures, leasehold improvements, capital leases and computer equipment and are recorded at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized using the straight-line method over the remaining lease term or the life of the asset, whichever is shorter.
	Description	Estimated Useful Life
	Office equipment and furniture	5 to 7 years
	Leasehold improvements	3 years
	Computer equipment	3 years
	Equipment under capitalized lease	Over life of lease
Fair Value of Financial Instruments	(e) Fair Value of Financial Instruments
	The Company measures fair value in accordance with generally accepted accounting principles. Fair value measurements are applied under other accounting pronouncements that require or permit fair value measurements. Financial instruments included in the Company’s balance sheets consist of cash and cash equivalents, accounts payable, accrued expenses, due to related parties, and derivative liability. The carrying amounts of these instruments reasonably approximate their fair values due to their short-term maturities.
Convertible Debentures and Warrant Liability	(f) Convertible Debentures and Warrant Liability
	The Company accounts for the convertible debentures and warrants issued in connection with the 2013 Purchase Agreement, the 2012 Purchase Agreement and the 2010 Purchase Agreement (see Note 10) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.
Concentration of Credit Risk	(g) Concentration of Credit Risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and is insured to the maximum limitations. Balances in these accounts may exceed federally insured limits at times, which expose the Company to institutional risk.
Research and Development	(h) Research and Development
	Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
Stock-based compensation	(i) Stock-Based Compensation
	Stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the required service period, which is generally equal to the vesting period. Share-based compensation is recognized only for those awards that are ultimately expected to vest.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model.  The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.
Basic and Diluted Income/(Loss) per Common Share	(j) Basic and Diluted Income/(Loss) per Common Share
	Basic net income/(loss) per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is calculated based on the weighted-average number of shares of common stock and other dilutive securities outstanding during the period. The potential dilutive shares of common stock resulting from the assumed exercise of stock options and warrants are determined under the treasury stock method.
	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income/(loss) per share.
		Year Ended December 31,
		2014		2013
	Numerator:
	Net income/(loss)	$	7,770,767	$	-39,656,975
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share		20,381,554		7,516,223
	Effect of dilutive securities:
	Warrants to purchase common stock		4,428,441		-
	Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share		24,809,995		7,516,223
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.
	As of December 31, 2014 and 2013, potentially dilutive securities include:
		Year Ended December 31,
		2014		2013
	Warrants to purchase common stock		4,455,231		34,181,166
	Options to purchase common stock		-		5,594,151
	Total potentially dilutive securities		4,455,231		39,775,317
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net income/(loss) per share if their effect is anti-dilutive. The aggregate number of common equivalent shares (related to options, warrants and convertible debentures) that have been excluded from the computations of diluted net income/(loss) per common share at December 31, 2014 and 2013 were 50,867,639 and 13,966,897, respectively, as their exercise prices are greater than the fair market price per common share as of December 31, 2014 and 2013, respectively.
Comprehensive Loss	(k) Comprehensive Loss
	The Company has no components of other comprehensive loss other than its net loss, and accordingly, comprehensive loss is equal to net loss for all periods presented.
Income Taxes	(l) Income Taxes
	The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the period in which the differences are expected to affect taxable income. The Company provides a valuation allowance when it appears more likely than not that some or all of the net deferred tax assets will not be realized. The Company has not performed an Internal Revenue Section 382 limitation study. Depending on the outcome of such study, the gross amount of net operating losses recognized in future tax periods could be limited.
	A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded.
	The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2014 and 2013 respectively. In addition, the Company had no amounts accrued for interest and penalties as of December 31, 2014 and 2013, respectively.
Recently Issued Accounting Pronouncements	(m) Recently Issued Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The objective of the amendments in this Update is to eliminate requirements for entities which have either not commenced principal operations or have not generated significant revenue from principal operations to present inception-to-date information in the financial statements. In addition, the Update eliminated the exception for evaluating such entities as possible variable interest entities.
	The Company elected to early adopt this guidance as permitted for its financial statements for the year ending December 31, 2014. As a result of adopting this guidance, the Company has retrospectively removed the inception-to-date financial results that have been historically included in the financial statements. Further, the Company has disclosed information about the risks and uncertainties related to the activities in which the Company is currently engaged and information about the intended operations of the Company.
	In August 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements-Going Concern (Topic 205-40)” (“ASU 2014-15”). Under the standard, management is required to evaluate for each annual and interim reporting period whether it is a probable that the entity will not be able to meet its obligations as they become due within one year after the date that financial statements are issued, or are available to be issued, where applicable.  ASU 2014-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for the Company on January 1, 2017. The Company will be evaluating the impact, if any, that the standard will have on its financial condition, results of operations, and disclosures in the near future.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Estimated Useful Life Of Property and Equipment	Description	Estimated Useful Life
	Office equipment and furniture	5 to 7 years
	Leasehold improvements	3 years
	Computer equipment	3 years
	Equipment under capitalized lease	Over life of lease
basic and diluted net income/(loss) per share	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income/(loss) per share.
		Year Ended December 31,
		2014		2013
	Numerator:
	Net income/(loss)	$	7,770,767	$	-39,656,975
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share		20,381,554		7,516,223
	Effect of dilutive securities:
	Warrants to purchase common stock		4,428,441		-
	Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share		24,809,995		7,516,223
Potentially Dilutive Securities	As of December 31, 2014 and 2013, potentially dilutive securities include:
		Year Ended December 31,
		2014		2013
	Warrants to purchase common stock		4,455,231		34,181,166
	Options to purchase common stock		-		5,594,151
	Total potentially dilutive securities		4,455,231		39,775,317

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment as of December 31, 2014 and 2013 consist of the following:
		2014		2013
	Computer equipment and software	$	17,721	$	17,721
	Office furniture and equipment		72,338		52,242
	Leasehold improvements		8,449		8,449
	Capital leases- equipment		11,500		-
	Total property and equipment		110,008		78,412
	Accumulated depreciation		-79,278		-66,692
	Total property and equipment, net	$	30,730	$	11,720

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule Of Accrued Liabilities	Accrued liabilities as of December 31, 2014 and 2013 consist of the following:
		2014		2013
	Accrued compensation and related benefits	$	407,497	$	439,156
	Accrued severance		250,605		-
	Accrued research and development expenses		744,240		316,099
	Accrued other expenses		7,951		170,000
		$	1,410,293	$	925,255

CONVERTIBLE_DEBENTURES_Tables

CONVERTIBLE DEBENTURES (Tables)	12 Months Ended
	Dec. 31, 2014
Convertible Notes Payable [Abstract]
Schedule of Fair Values on Issuance of Debt Warrant and Debt Conversion Feature	The following table reflects the debt discount for the 2012 Warrants and the embedded conversion feature of the Debentures at their fair values on issuance:
		Issuance
	Debentures, principal		14,857,200
	2012 Warrant liability		-12,430,524
	Debenture conversion feature		-7,548,500
			-5,121,824
Interest Income And Interest Expense	The following table illustrates the components of total interest expense for 2014 and 2013 incurred under the Debentures.
		Year Ended December 31,
	Interest Expense	2014		2013
	Note conversion discount	$	—	$	14,366,161
	Interest expense on 2012 debentures		—		2,174,244
	Amortized deferred financing fees		—		1,709,531
	Liquidated damages on 2012 debentures		—		319,221
	Total Interest Expense	$	—	$	18,569,157

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2014:
					Quoted Market
					Prices in Active			Significant Other		Significant Other
		Fair Value			Markets			Observable Inputs		Unobservable Inputs
		Dec 31, 2014			(Level 1)			(Level 2)		(Level 3)
	Liabilities:
	Warrant liability - 2010 Series B	$	28,066		$	-		$	-	$	28,066
	Warrant liability - 2012 Series A&B		3,520,319			-			-		3,520,319
	Warrant liability - 2012 placement agent		67,246			-			-		67,246
	Warrant liability - 2013 Series D&E		3,036,986			-			-		3,036,986
	Warrant liability - 2013 placement agent		18,907			-			-		18,907
	Total	$	6,671,524		$	-		$	-	$	6,671,524
	The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2013:
					Quoted Market
					Prices in Active			Significant Other		Significant Other
		Fair Value			Markets			Observable Inputs		Unobservable Inputs
		December 31, 2013			(Level 1)			(Level 2)		(Level 3)
	Liabilities:
	Warrant liability - 2010 Series B	$	362,452		$	-		$	-	$	362,452
	Warrant liability - 2012 Series A&B		16,703,983			-			-		16,703,983
	Warrant liability - 2012 placement agent		362,633			-			-		362,633
	Warrant liability - 2013 Series D&E		18,337,733			-			-		18,337,733
	Warrant liability - 2013 placement agent		98,080			-			-		98,080
	Total	$	35,864,881		$	-		$	-	$	35,864,881
Summary of Changes in Fair Value of Liabilities	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held at December 31, 2014:
	Fair Value Measurement Using Significant Unobservable Inputs (Level 3)
		Total								2013						2012				Debenture
		Warrant			2013			2013		Placement		2012		2012		Placement		2010		Conversion
		Liability			Series E			Series D		Agent		Series B		Series A		Agent		Series B		Feature
	Balance at January 1, 2013	$	21,420,276		$	-		$	-	$	-	$	5,744,784	$	6,685,740	$	542,530	$	898,722	$	7,548,500
	Purchase, sales and settlements:
	Warrants and other derivatives issued		15,681,151			5,057,354			10,552,240		71,557
	Settlement of derivatives		-5,403,000																		-5,403,000
	Total gains or losses:
	Unrealized depreciation/(appreciation)		4,166,454			797,852			1,930,287		26,523		-2,928,108		7,201,567		-179,897		-536,270		-2,145,500
	Balance at January 1, 2014	$	35,864,881		$	5,855,206		$	12,482,527	$	98,080	$	2,816,676	$	13,887,307	$	362,633	$	362,452	$	-
	Purchase, sales and settlements:
	Warrants and other derivatives issued
	Settlement of derivatives
	Total gains or losses:
	Unrealized depreciation/(appreciation)		-29,193,357			-5,829,469			-9,471,278		-79,173		-2,804,295		-10,379,369		-295,387		-334,386
	Balance at Dec 31, 2014	$	6,671,524		$	25,737		$	3,011,249	$	18,907	$	12,381	$	3,507,938	$	67,246	$	28,066	$	-
	Value per Warrant	$	0.154		$	0.002		$	0.234	$	0.288	$	0.002	$	0.34	$	0.237	$	0.035
Schedule of Derivative Liabilities at Fair Value	Significant assumptions used at December 31, 2014 and 2013 for the warrants and embedded conversion discount derivative liability of the Debentures are as follows:
		December 31, 2014			December 31, 2013
	Volatility		173	%		108	%
	Risk-free interest rate		1.65	%		2.08	%

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Summary of All Outstanding Warrants to Purchase Shares of Common Stock	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of December 31, 2014.
	Grant Date	Warrants		Exercise		Weighted		Expiration		Exercised		Warrants
		Issued		Price		Average		Date				Outstanding
						Exercise
						Price
	9/3/10		801,885	$	3.55	$	3.55		9/3/15		-		801,885
	9/3/10		132,116	$	8.8	$	8.8		9/3/15		-		132,116
	11/26/12		5,293,738	$	2.4	$	2.4		1/31/15		-		5,293,738
	12/18/12		896,748	$	2.4	$	2.4		1/31/15		-		896,748
	11/26/12		8,822,887	$	2.4	$	2.4		11/26/17		-		8,822,887
	11/26/12		261,250	$	2.64	$	2.64		11/26/17		-		261,250
	12/18/12		1,494,577	$	2.4	$	2.4		12/18/17		-		1,494,577
	12/18/12		22,500	$	2.64	$	2.64		12/18/17		-		22,500
	10/29/13		4,455,231	$	0.01	$	0.01		10/29/18		-		4,455,231
	10/29/13		12,868,585	$	2.4	$	2.4		1/31/15		-		12,868,585
	10/29/13		12,868,585	$	4	$	4		10/29/18		-		12,868,585
	10/29/13		65,650	$	2.64	$	2.64		10/29/18		-		65,650
			47,983,752			$	2.65				-		47,983,752

STOCK_OPTION_PLAN_Tables

STOCK OPTION PLAN (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of Share-based Compensation, Activity	During the years ended December 31, 2014 and December 31, 2013 the Company issued the following stock options:
			Year Ended December 31,
			2014			2013
	Options granted			2,423,742			5,038,605
Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model	The following assumptions were used for the years ended December 31, 2014 and 2013:
			Year Ended December 31,
			2014			2013
	Expected volatility			86% - 92%			89% - 96%
	Expected term			6 years			4-6 years
	Dividend yield			0.00%			0.00%
	Risk- free interest rate			1.57% - 1.63%			0.77% - 1.35%
	Stock price			$0.85 - $2.90			$2.40
	Forfeiture rate			0.00%			0.00%
Summary of Status of Options Issued And Changes in Options Outstanding	A summary of the status of the options issued under the Plan at December 31, 2014, and information with respect to the changes in options outstanding is as follows:
			Number of			Weighted-			Aggregate
			Shares			Average			Intrinsic
						Exercise			Value
						Price
	Options outstanding at December 31, 2013			5,758,463		$	2.66		$	-
	Granted			2,423,742		$	2.66			-
	Exercised			-			-			-
	Cancelled			-843,087		$	3.23			-
	Options outstanding at December 31, 2014			7,339,118		$	2.59		$	-
	Options vested and expected to vest at December 31, 2014			7,339,118		$	2.59		$	-
	Exercisable at December 31, 2014			2,741,476		$	2.81		$	-
	Shares available for grant under the 2005 Plan			3,776,197
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2014:
				Outstanding								Exercisable
	Exercise Price			Number of			Weighted-			Weighted-		Number of		Weighted-
				Shares			Average			Average		Shares		Average
							Remaining			Exercise				Exercise Price
							Contractual			Price
							Life (Years)
	$	0.85			136,785			9.84		$	0.85		3,799	$	0.85
	$	1.3			100,000			9.77		$	1.3		-	$	1.3
	$	2.23			223,445			9.15		$	2.23		-	$	2.23
	$	2.4			5,227,589			8.19		$	2.4		2,387,170	$	2.4
	$	2.9			1,548,916			9.07		$	2.9		248,124	$	2.9
	$	8			65,000			5.57		$	8		65,000	$	8
	$	19.38			37,383			3.28		$	19.38		37,383	$	19.38
	Total				7,339,118			8.41		$	2.59		2,741,476	$	2.81
Stock-Based Compensation Costs	Stock-based compensation costs under the Plan for the year ended December 31, 2014 and 2013 are as follows:
			Year ended December 31,
			2014			2013
	Research and development		$	979,792		$	572,741
	General and administrative			3,543,876			884,035
	Total		$	4,523,668		$	1,456,776

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s net deferred tax assets at December 31, 2014 and 2013 are shown below.
		For Year Ended December 31,
		2014			2013
	Non-current deferred tax assets:
	Net operating loss carry forwards	$	30,133,600		$	22,489,800
	Research tax credit		3,267,000			2,873,000
	Accrued expenses		267,000			-
	Stock based compensation		2,451,000			437,000
	Total deferred tax assets		36,118,600			25,799,800
	Non-current deferred tax liability:
	Bonus Section 401 adjustment		-61,000			-91,000
	Depreciation and amortization		-			-5,000
	Total net deferred tax assets		36.057.600			25,703,800
	Valuation allowance		-36,057,600			-25,703,800
	Net deferred tax assets	$	-		$	-
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2014 and 2013 are as follows:
		2014			2013
	Federal Tax		34	%		34	%
	State Tax		6.6	%		5.9	%
	Interest Expense		-152.5	%		-
	Incentive stock options		-			3.6	%
	R&D credit		-6.8	%		2.7	%
	Other adjustments		-14.6	%		-
	Valuation allowance/other		133.3	%		-46.2	%
	Net		-			-

LEASES_COMMITMENTS_AND_CONTING1

LEASES, COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments under operating leases	Future minimum lease payments under operating leases as of December 31, 2014 are as follows:
	2015	$	62,885
	2016		64,430
	2017		66,514
	2018		5,557
	Total future minimum lease payments	$	199,386
Future minimum lease payments under capital leases	Future minimum lease payments under capital leases together with the present value of the net minimum lease payments as of December 31, 2014 are as follows;
	2015	$	4,778
	2016		4,778
	2017		4,380
	Total net future minimum lease payments		13,936
	Less: Amount representing interest		-2,691
	Present value of net minimum lease payments	$	11,245

Description_of_Business_Additi

Description of Business - Additional Information (Detail)	Dec. 31, 2014
Organization and Nature of Operations [Line Items]
Percentage of outstanding common stock collectively held by former stockholders of Old Arno	95.00%

Recovered_Sheet1

Liquidity and Capital Resources - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Working Capital Detail [Line Items]
Cash and cash equivalents	$7,948,436	$26,774,203	$10,943,437

Recovered_Sheet2

The Merger and Basis of Presentation - Additional Information (Detail) (USD $)	0 Months Ended
	Jun. 02, 2008	Jun. 03, 2008
Merger and Basis of Presentation [Line Items]
Number of shares issued on conversion of 6% notes	1,962,338
Accumulated deficit		$120,538
Common Stock
Merger and Basis of Presentation [Line Items]
Number of securities called by warrants	196,189
Per share exercise price of warrant	$2.42
Old Arno
Merger and Basis of Presentation [Line Items]
Shares issuable prior to merger ratio		$1.99
Shares issued in merger		1,611,760
Ownership interest		95.00%
Number of shares issued in business combination	7,360,700
Gross proceeds private placement	$17,732,000
Sale of Stock	3,691,900
Notes interest rate	6.00%
Number of shares issued on conversion of 6% notes	984,246
Number of securities called by warrants	98,409
Per share exercise price of warrant	$4.83
Warrant expiration term		5 years
Laurier International Inc
Merger and Basis of Presentation [Line Items]
Shares issued in merger		19,291,824
Common stock outstanding prior to merger		1,100,200
Common stock issued prior to merger		1,100,200

Recovered_Sheet3

Summary of Significant Accounting Policies - Additional Information (Detail) (Options, Warrants and Convertible Debentures)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Options, Warrants and Convertible Debentures
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	50,867,639	13,966,897

Straight_Line_Method_over_Rema

Straight - Line Method over Remaining Lease Term or Life of Asset (Detail)	12 Months Ended
	Dec. 31, 2014
Office equipment and furniture | Maximum
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Office equipment and furniture | Minimum
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold improvements
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer equipment
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment under capitalized lease
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life Description	Over life of lease

Basic_and_diluted_net_incomelo

Basic and diluted net income/(loss) per share (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net income/(loss)	$7,770,767	($39,656,975)
Denominator:
Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share	20,381,554	7,516,223
Effect of dilutive securities:
Warrants to purchase common stock	4,428,441	0
Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share	24,809,995	7,516,223

Potentially_Dilutive_Securitie

Potentially Dilutive Securities (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Purchase common stock	4,455,231	39,775,317
Warrants to purchase common stock
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Purchase common stock	4,455,231	34,181,166
Options to purchase common stock
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Purchase common stock	0	5,594,151

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$12,586	$13,117

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Computer equipment and software	$17,721	$17,721
Office furniture and equipment	72,338	52,242
Leasehold improvements	8,449	8,449
Capital leases- equipment	11,500	0
Total property and equipment	110,008	78,412
Accumulated depreciation	-79,278	-66,692
Total property and equipment, net	$30,730	$11,720

Recovered_Sheet4

Intangible Assets and Intellectual Property - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended		12 Months Ended
	Apr. 01, 2014	Feb. 13, 2012	Jan. 31, 2014	Oct. 31, 2013	Dec. 31, 2008
Finite-Lived Intangible Assets [Line Items]
Services agreement expire date		30-Apr-14
Services agreement monthly payment	$50,000	$70,833
Onapristone License Agreement
Finite-Lived Intangible Assets [Line Items]
Written notice period for termination of license agreement if breach is not cured		90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement		500,000	100,000	150,000
Aggregate potential milestone payments		15,100,000
License agreement termination date		13-Feb-32
Prior written notice period for termination of license agreement by the company for any reason		90 days
AR-12 and AR-42 License Agreements | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement					450,000
Written notice period for termination of license agreement if breach is not cured					90 days
Prior written notice period for termination of license agreement by the company for any reason					90 days
License agreement expiration date					20 years
AR-12 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments					6,100,000
Potential milestone payments, due after market approval					5,000,000
AR-42 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments					5,100,000
Potential milestone payments, due after market approval					$4,000,000

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued compensation and related benefits	$407,497	$439,156
Accrued severance	250,605	0
Accrued research and development expenses	744,240	316,099
Accrued other expenses	7,951	170,000
Total	$1,410,293	$925,255

Convertible_Debentures_Additio

Convertible Debentures - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Oct. 29, 2013

Mar. 25, 2013

Mar. 26, 2013

Mar. 27, 2013

Dec. 18, 2012

Nov. 26, 2012

Dec. 31, 2014

Dec. 31, 2013

31-May-13

27-May-13

Apr. 29, 2013

Mar. 31, 2013

Dec. 31, 2012

Dec. 26, 2012

Proceeds From Issuance Of Convertible Debt And Warrant

$14,900,000

Placement Agent Fees And Other Transaction Related Expenses

1,200,000

Minimum Subsequent Equity Financing

12,000,000

Long-term Debt, Gross

14,857,200

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

6,190,500

Interest Expense, Debt

0

18,569,157

Amortization of Debt Discount (Premium)

10,600,000

0

14,900,000

Per Share Coversion Price For Liquidated Damages

$2.40

Number Of Shares Issued On Conversion Of 2012 Debentures

6,530,154

Debt Instrument, Convertible, Conversion Price

$2.40

Shares Issued, Price Per Share

$2.40

Common Stock Issuable Payment

100.00%

Registration Payment Arrangement Defalt Percentage Of Liquidated Damages

2.00%

2.00%

Registrable Securities Percentage

100.00%

Registration Payment Arrangement, Maximum Potential Consideration

900,000

Debt Instrument, Convertible, Beneficial Conversion Feature

7,548,500

Total value of 2012 Series A & B warrants

-12,430,524

Stock Issued For Accrued And Unpaid Interest

345,606

494,764

Interest Expense On Inducement To Convert Debentures

1,187,433

Warrant [Member]

Total value of 2012 Series A & B warrants

12,430,524

Common Stock [Member]

Stock Issued During Period, Shares In Lieu Of Cash

380,606

First Installement [Member]

Liquated Damages Under Registration Rights Agreement

297,148

Second installement [Member]

Liquated Damages Under Registration Rights Agreement

327,688

Third and Final Installement [Member]

Liquated Damages Under Registration Rights Agreement

288,674

8% Senior Convertible Debentures

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debentures [Member]

Long-term Debt, Gross

$12,230,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Interest Rate, Effective Percentage

8.00%

Registrable Securities Percentage

80.00%

Debt Instrument, Maturity Date, Description

2015

Series A Warrant [Member]

Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights

6,190,500

Class of Warrant or Right, Exercise Price of Warrants or Rights

$4

Common Stock Issuable Payment

100.00%

Warrant Term

5 years

Series B Warrant [Member]

Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights

6,190,500

Class of Warrant or Right, Exercise Price of Warrants or Rights

$2.40

Warrant Term

18 months

Common Stock Issuable Upon Conversion Of Debentures

150.00%

Debt_Discount_for_2012_Warrant

Debt Discount for 2012 Warrants and Embedded Conversion Feature of Debentures (Detail) (USD $)	Dec. 31, 2012
Debentures, principal	$14,857,200
2012 Warrant liability	-12,430,524
Debenture conversion feature	-7,548,500
Total	($5,121,824)

Components_of_Interest_Expense

Components of Interest Expense Related to Convertible Debentures (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note conversion discount	$0	$14,366,161
Interest expense on 2012 debentures	0	2,174,244
Amortized deferred financing fees	0	1,709,531
Liquidated damages on 2012 debentures	0	319,221
Total Interest Expense	$0	$18,569,157

Fair_Value_Hierarchy_for_Liabi

Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Liabilities
Derivative Liabilities Noncurrent	$6,671,524	$35,864,881
Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	6,671,524	35,864,881
Fair Value, Measurements, Recurring | Warrant liability - 2010 Series B
Liabilities
Derivative Liabilities Noncurrent	28,066	362,452
Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B
Liabilities
Derivative Liabilities Noncurrent	3,520,319	16,703,983
Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	67,246	362,633
Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E
Liabilities
Derivative Liabilities Noncurrent	3,036,986	18,337,733
Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	18,907	98,080
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Series B
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Series B
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	6,671,524	35,864,881
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Series B
Liabilities
Derivative Liabilities Noncurrent	28,066	362,452
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B
Liabilities
Derivative Liabilities Noncurrent	3,520,319	16,703,983
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	67,246	362,633
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E
Liabilities
Derivative Liabilities Noncurrent	3,036,986	18,337,733
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	$18,907	$98,080

Summary_of_Changes_in_Fair_Val

Summary of Changes in Fair Value of Liabilities (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
2013 Series E
Warrant Liability
Balance	$5,855,206	$0
Purchases, sales and settlements:
Warrants and other derivatives issued		5,057,354
Total gains or losses:
Unrealized depreciation (appreciation)	-5,829,469	797,852
Balance	25,737	5,855,206
Value per Warrant	$0.00
2013 Series D
Warrant Liability
Balance	12,482,527	0
Purchases, sales and settlements:
Warrants and other derivatives issued		10,552,240
Total gains or losses:
Unrealized depreciation (appreciation)	-9,471,278	1,930,287
Balance	3,011,249	12,482,527
Value per Warrant	$0.23
2013 Placement Agent
Warrant Liability
Balance	98,080	0
Purchases, sales and settlements:
Warrants and other derivatives issued		71,557
Total gains or losses:
Unrealized depreciation (appreciation)	-79,173	26,523
Balance	18,907	98,080
Value per Warrant	$0.29
2012 Series B
Warrant Liability
Balance	2,816,676	5,744,784
Total gains or losses:
Unrealized depreciation (appreciation)	-2,804,295	-2,928,108
Balance	12,381	2,816,676
Value per Warrant	$0.00
2012 Series A
Warrant Liability
Balance	13,887,307	6,685,740
Total gains or losses:
Unrealized depreciation (appreciation)	-10,379,369	7,201,567
Balance	3,507,938	13,887,307
Value per Warrant	$0.34
2012 Placement Agent
Warrant Liability
Balance	362,633	542,530
Total gains or losses:
Unrealized depreciation (appreciation)	-295,387	-179,897
Balance	67,246	362,633
Value per Warrant	$0.24
2010 Series B
Warrant Liability
Balance	362,452	898,722
Total gains or losses:
Unrealized depreciation (appreciation)	-334,386	-536,270
Balance	28,066	362,452
Value per Warrant	$0.04
Warrant
Warrant Liability
Balance	35,864,881	21,420,276
Purchases, sales and settlements:
Warrants and other derivatives issued		15,681,151
Settlement of derivatives		-5,403,000
Total gains or losses:
Unrealized depreciation (appreciation)	-29,193,357	4,166,454
Balance	6,671,524	35,864,881
Value per Warrant	$0.15
Debenture Conversion Feature
Warrant Liability
Balance		7,548,500
Purchases, sales and settlements:
Settlement of derivatives		-5,403,000
Total gains or losses:
Unrealized depreciation (appreciation)		-2,145,500
Balance	$0	$0

Warrants_and_Embedded_Conversi

Warrants and Embedded Conversion Discount Derivative Liability (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Volatility	173.00%	108.00%
Risk-free interest rate	1.65%	2.08%

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended		1 Months Ended	12 Months Ended		1 Months Ended
	Oct. 29, 2013	Oct. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	27-May-13	Dec. 31, 2014	Dec. 31, 2010	Mar. 27, 2013	Apr. 29, 2013	Oct. 31, 2014
Stockholders Equity Note [Line Items]
Issuance of common shares in lieu of liquidated damages (in dollars)			$913,510
Common stock, shares issued			20,370,331			20,408,616
Common stock, shares outstanding			20,370,331			20,408,616
Derivative liabilities			35,864,881			6,671,524
Stockholders equity reverse stock split	1-for-8 as of October 29, 2013 (the Reverse Split).
Sale Of Stock Units	12,826,752	41,833
Stock Units Issued Related Cost	760,000
Gross Proceeds From Issuance Of Units	30,840,000
Potential Additional Equity Financing				12,000,000
Purchase Agreement and 2013 Purchase Agreement
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$3.55
Third And Final Installments
Stockholders Equity Note [Line Items]
Issuance of common shares in lieu of liquidated damages (in shares)					120,280
Issuance of common shares in lieu of liquidated damages (in dollars)					288,674
Common Shares
Stockholders Equity Note [Line Items]
Sale Of Stock Units	12,868,585
Shares Of Common Stock Reserved For Issuance Upon The Exercise Of Outstanding Options And Warrants						55,322,870
Maxim Group Llc
Stockholders Equity Note [Line Items]
Common stock, shares issued				7,500
Number of securities called by warrants				283,750
Class of Warrant or Right, Exercise Price of Warrants or Rights				$2.64
Warrant Term				5 years
Derivative liabilities			400,000			100,000
Placement Fee Paid				1,035,000
Class A Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants				6,190,500			152,740
Class of Warrant or Right, Exercise Price of Warrants or Rights				$4			$8
Warrant Term				5 years			2 years 6 months
Class B Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants				6,190,500			801,885
Class of Warrant or Right, Exercise Price of Warrants or Rights				$2.40			$9.20
Warrant Term				18 months			5 years
Series C Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.01
Warrant Term			5 years
Series D Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						4
Warrant Term			5 years
2010 Class A Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants							152,704
Class A and B Warrants
Stockholders Equity Note [Line Items]
Derivative liabilities			400,000			0
First Installment
Stockholders Equity Note [Line Items]
Issuance of common shares in lieu of liquidated damages (in shares)								123,809
Issuance of common shares in lieu of liquidated damages (in dollars)								297,144
Second Installment
Stockholders Equity Note [Line Items]
Issuance of common shares in lieu of liquidated damages (in shares)									136,536
Issuance of common shares in lieu of liquidated damages (in dollars)									327,688
Securities Purchase and Registration Rights Agreement | Series C Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						0.01
Securities Purchase and Registration Rights Agreement | Series D Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$4
Securities Purchase and Registration Rights Agreement | Series E Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$2.40
Series D Warrants and Series E Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants	8,413,354
Class of Warrant or Right, Exercise Price of Warrants or Rights	$2.40
Derivative liabilities			18,300,000			3,000,000
Stock Issued During Period, Shares, Conversion of Units	8,413,354
Sale Of Stock Units	8,413,354
Series C Warrants, Series D Warrants and Series E Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants						4,455,231
Class of Warrant or Right, Exercise Price of Warrants or Rights						2.39
Sale Of Stock Units	4,455,231
Series A and B Warrants
Stockholders Equity Note [Line Items]
Derivative liabilities			$16,700,000			3,500,000

Summary_of_All_Outstanding_War

Summary of All Outstanding Warrants to Purchase Shares of Common Stock (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Warrant 1
Class of Warrant or Right [Line Items]
Grant Date	3-Sep-10
Warrants Issued	801,885
Exercise Price	$3.55
Weighted Average Exercise Price	$3.55
Expiration Date	3-Sep-15
Exercised	0
Warrants Outstanding	801,885
Warrant 2
Class of Warrant or Right [Line Items]
Grant Date	3-Sep-10
Warrants Issued	132,116
Exercise Price	$8.80
Weighted Average Exercise Price	$8.80
Expiration Date	3-Sep-15
Exercised	0
Warrants Outstanding	132,116
Warrant 3
Class of Warrant or Right [Line Items]
Grant Date	26-Nov-12
Warrants Issued	5,293,738
Exercise Price	$2.40
Weighted Average Exercise Price	$2.40
Expiration Date	31-Jan-15
Exercised	0
Warrants Outstanding	5,293,738
Warrant 4
Class of Warrant or Right [Line Items]
Grant Date	18-Dec-12
Warrants Issued	896,748
Exercise Price	$2.40
Weighted Average Exercise Price	$2.40
Expiration Date	31-Jan-15
Exercised	0
Warrants Outstanding	896,748
Warrant 5
Class of Warrant or Right [Line Items]
Grant Date	26-Nov-12
Warrants Issued	8,822,887
Exercise Price	$2.40
Weighted Average Exercise Price	$2.40
Expiration Date	26-Nov-17
Exercised	0
Warrants Outstanding	8,822,887
Warrant 6
Class of Warrant or Right [Line Items]
Grant Date	26-Nov-12
Warrants Issued	261,250
Exercise Price	$2.64
Weighted Average Exercise Price	$2.64
Expiration Date	26-Nov-17
Exercised	0
Warrants Outstanding	261,250
Warrant 7
Class of Warrant or Right [Line Items]
Grant Date	18-Dec-12
Warrants Issued	1,494,577
Exercise Price	$2.40
Weighted Average Exercise Price	$2.40
Expiration Date	18-Dec-17
Exercised	0
Warrants Outstanding	1,494,577
Warrant 8
Class of Warrant or Right [Line Items]
Grant Date	18-Dec-12
Warrants Issued	22,500
Exercise Price	$2.64
Weighted Average Exercise Price	$2.64
Expiration Date	18-Dec-17
Exercised	0
Warrants Outstanding	22,500
Warrant 9
Class of Warrant or Right [Line Items]
Grant Date	29-Oct-13
Warrants Issued	4,455,231
Exercise Price	$0.01
Weighted Average Exercise Price	$0.01
Expiration Date	29-Oct-18
Exercised	0
Warrants Outstanding	4,455,231
Warrant 10
Class of Warrant or Right [Line Items]
Grant Date	29-Oct-13
Warrants Issued	12,868,585
Exercise Price	$2.40
Weighted Average Exercise Price	$2.40
Expiration Date	31-Jan-15
Exercised	0
Warrants Outstanding	12,868,585
Warrant 11
Class of Warrant or Right [Line Items]
Grant Date	29-Oct-13
Warrants Issued	12,868,585
Exercise Price	$4
Weighted Average Exercise Price	$4
Expiration Date	29-Oct-18
Exercised	0
Warrants Outstanding	12,868,585
Warrant 12
Class of Warrant or Right [Line Items]
Grant Date	29-Oct-13
Warrants Issued	65,650
Exercise Price	$2.64
Weighted Average Exercise Price	$2.64
Expiration Date	29-Oct-18
Exercised	0
Warrants Outstanding	65,650
Total Warrants
Class of Warrant or Right [Line Items]
Warrants Issued	47,983,752
Weighted Average Exercise Price	$2.65
Exercised	0
Warrants Outstanding	47,983,752

Stock_Option_Plan_Additional_I

Stock Option Plan - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended
	Nov. 04, 2013	Dec. 31, 2014	Dec. 31, 2013	Oct. 07, 2013	Jan. 14, 2013	Apr. 25, 2011	Jun. 03, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted under 2005 Plan (in years)		8 years 4 months 28 days
Fair value of options vested under 2005 Plan		$3,828,561	$1,507,982
Total unrecognized estimated compensation cost related to stock options		$8,436,724
Total unrecognized estimated compensation cost related to stock options, recognition period		2 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,423,742	5,038,605
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	36 equal monthly installments
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted under 2005 Plan (in years)		10 years
Stock Options, Warrants Restricted Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant		3,776,197
Glenn Mattes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity Method Investment, Ownership Percentage				5.50%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	386,697
Alexander Zukiwski
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity Method Investment, Ownership Percentage				4.50%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	316,389
Stefan Proniuk
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity Method Investment, Ownership Percentage				0.65%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	45,701
Director Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity Method Investment, Ownership Percentage	0.10%
Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price	2.4
Percentage Of Stock Granted To Purchase Common Stock	0.20%
Arie Belldegrun
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity Method Investment, Ownership Percentage	5.00%
Steven Ruchefsky
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity Method Investment, Ownership Percentage	0.20%
2005 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance under 2005 Plan					945,276	875,000	373,831
Term of stock options granted under 2005 Plan (in years)				10 years
2005 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance under 2005 Plan				11,155,295
2005 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance under 2005 Plan				945,276
Conversion Debentures Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price	2.4

Options_Granted_Detail

Options Granted (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted	2,423,742	5,038,605

Assumptions_Used_in_Estimating

Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Term	6 years
Dividend yield	0.00%	0.00%
Stock price		$2.40
Forfeiture rate	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Volatility	86.00%	89.00%
Expected Term		4 years
Risk-free interest rate	1.57%	0.77%
Stock price	$0.85
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Volatility	92.00%	96.00%
Expected Term		6 years
Risk-free interest rate	1.63%	1.35%
Stock price	$2.90

Summary_of_Status_of_Options_I

Summary of Status of Options Issued and Changes in Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Number of Shares
Balance at December 31, 2014	7,339,118
Exercisable at December 31, 2014	2,741,476
Weighted-Average Exercise Price
Balance at December 31, 2014	$2.59
Exercisable at December 31, 2014	$2.81
Stock Option Plan
Number of Shares
Balance at December 31, 2013	5,758,463
Options granted	2,423,742
Options exercised	0
Options cancelled	-843,087
Balance at December 31, 2014	7,339,118
Options vested and expected to vest at December 31, 2014	7,339,118
Exercisable at December 31, 2014	2,741,476
Shares available for grant under the 2005 Plan	3,776,197
Weighted-Average Exercise Price
Balance at December 31, 2013	$2.66
Options granted	$2.66
Options exercised	$0
Options cancelled	$3.23
Balance at December 31, 2014	$2.59
Options vested and expected to vest at December 31, 2014	$2.59
Exercisable at December 31, 2014	$2.81
Aggregate Intrinsic Value
Balance at December 31, 2013	$0
Options granted	0
Options exercised	0
Options cancelled	0
Balance at December 31, 2014	0
Options vested and expected to vest at December 31, 2014	0
Exercisable at December 31, 2014	$0

Summary_of_Information_about_S

Summary of Information about Stock Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares	7,339,118
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 4 months 28 days
Options Outstanding, Weighted-Average Exercise Price	$2.59
Options Exercisable, Shares	2,741,476
Options Exercisable, Weighted- Average Exercise Price	$2.81
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$0.85
Options Outstanding, Shares	136,785
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 10 months 2 days
Options Outstanding, Weighted-Average Exercise Price	$0.85
Options Exercisable, Shares	3,799
Options Exercisable, Weighted- Average Exercise Price	$0.85
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$1.30
Options Outstanding, Shares	100,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 9 months 7 days
Options Outstanding, Weighted-Average Exercise Price	$1.30
Options Exercisable, Shares	0
Options Exercisable, Weighted- Average Exercise Price	$1.30
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$2.23
Options Outstanding, Shares	223,445
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 1 month 24 days
Options Outstanding, Weighted-Average Exercise Price	$2.23
Options Exercisable, Shares	0
Options Exercisable, Weighted- Average Exercise Price	$2.23
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$2.40
Options Outstanding, Shares	5,227,589
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 2 months 8 days
Options Outstanding, Weighted-Average Exercise Price	$2.40
Options Exercisable, Shares	2,387,170
Options Exercisable, Weighted- Average Exercise Price	$2.40
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$2.90
Options Outstanding, Shares	1,548,916
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 25 days
Options Outstanding, Weighted-Average Exercise Price	$2.90
Options Exercisable, Shares	248,124
Options Exercisable, Weighted- Average Exercise Price	$2.90
Exercise Price 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$8
Options Outstanding, Shares	65,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	5 years 6 months 25 days
Options Outstanding, Weighted-Average Exercise Price	$8
Options Exercisable, Shares	65,000
Options Exercisable, Weighted- Average Exercise Price	$8
Exercise Price 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$19.38
Options Outstanding, Shares	37,383
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	3 years 3 months 11 days
Options Outstanding, Weighted-Average Exercise Price	$19.38
Options Exercisable, Shares	37,383
Options Exercisable, Weighted- Average Exercise Price	$19.38

StockBased_Compensation_Costs_

Stock-Based Compensation Costs (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$4,523,668	$1,456,776
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	979,792	572,741
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$3,543,876	$884,035

Related_Parties_Additional_Inf

Related Parties - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Related Party Transaction [Line Items]
Amount payable to TRC	$26,039	$0
Total cash services and reimbursed expenses	347,927
Two River Consulting Llc
Related Party Transaction [Line Items]
Related party transactions total billed amount for services rendered	309,330
Amount payable to TRC	$55,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance	$36,057,600	$25,703,800
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		10,400,000
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$75,700,000	$53,300,000
Operating Loss Carry Forward Expiration Date	2026

Significant_Components_of_Net_

Significant Components of Net Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Non-current deferred tax assets:
Net operating loss carry forwards	$30,133,600	$22,489,800
Research tax credit	3,267,000	2,873,000
Accrued expenses	267,000	0
Stock based compensation	2,451,000	437,000
Total deferred tax assets	36,118,600	25,799,800
Non-current deferred tax liability:
Bonus Section 401 adjustment	-61,000	-91,000
Depreciation and amortization	0	-5,000
Total net deferred tax assets	36,057,600	25,703,800
Valuation allowance	-36,057,600	-25,703,800
Net deferred tax assets	$0	$0

Reconciliation_of_Statutory_Ta

Reconciliation of Statutory Tax Rates and Effective Tax Rates (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Effective Income Tax Rate Reconciliation [Line Items]
Federal Tax	34.00%	34.00%
State Tax	6.60%	5.90%
Interest Expense	-152.50%	0.00%
Incentive stock options	0.00%	3.60%
R&D credit	-6.80%	2.70%
Other adjustments	-14.60%	0.00%
Valuation allowance/other	133.30%	-46.20%
Net	0.00%	0.00%

Recovered_Sheet5

Leases, Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Jun. 17, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 04, 2011
				sqft
Leases, Commitments And Contingencies Disclosure [Line Items]
Deposits Assets, Noncurrent		$10,455	$10,455
Purchase Commitment, Remaining Minimum Amount Committed		7,300,000
Lease Expiration Date	31-Jan-18
Operating Leases, Future Minimum Payments Due		199,386
Description of Lessee Leasing Arrangements, Capital Leases		The lease has an initial term of three years and cannot be cancelled or terminated prior to the end of the initial lease term. After the end of the initial term the company can either enter into a new lease, purchase the equipment or return the equipment.
Flemington Lease
Leases, Commitments And Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense		84,833	81,081
Operating Leases, Future Minimum Payments Due		$199,386
Flemington Lease sqft
Leases, Commitments And Contingencies Disclosure [Line Items]
Area of Land				4,168

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments Under Operating Leases (Detail) (USD $)	Dec. 31, 2014
Future Minimum Rental Payments For Operating Leases [Line Items]
2015	$62,885
2016	64,430
2017	66,514
2018	5,557
Total future minimum lease payments	$199,386

Future_Minimum_Lease_Payments_1

Future Minimum Lease Payments Under Capital Leases (Detail) (USD $)	Dec. 31, 2014
Future Minimum Lease Payments For Capital Leases [Line Items]
2015	$4,778
2016	4,778
2017	4,380
Total net future minimum lease payments	13,936
Less: Amount representing interest	-2,691
Present value of net minimum lease payments	$11,245

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Subsequent Event [Line Items]
Class Of Warrant Or Righs Date On Which Warrants Or Rights Expire	31-Jan-15
Series B Warrants
Subsequent Event [Line Items]
Stock Issued During Period Shares New Issues	6,200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	2.4
Series E Warrants
Subsequent Event [Line Items]
Stock Issued During Period Shares New Issues	12,800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	2.4